Bausch Health Companies Inc(NYSE:BHC) 
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International...
Website: http://www.bauschhealth.com
Founded: 1959
Full Time Employees: 21,700
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2014-09-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2009-11-05 | 2009-08-06 | 2009-03-31 | 2009-02-26 | 2008-11-06 | 2008-08-13 | 2008-06-30 | 2008-05-31 | 2008-05-08 | 2008-03-17 | 2007-12-31 | 2007-11-12 | 2007-11-08 | 2007-08-09 | 2007-05-31 | 2007-05-18 | 2007-05-10 | 2007-03-31 | 2007-03-30 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenues | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
product sales | 2,500,000,000 | 2,768,000,000 | 2,657,000,000 | 2,504,000,000 | 2,227,000,000 | 2,528,000,000 | 2,482,000,000 | 2,379,000,000 | 2,129,000,000 | 2,382,000,000 | 2,213,000,000 | 2,146,000,000 | 1,922,000,000 | 2,175,000,000 | 2,026,000,000 | 1,947,000,000 | 1,898,000,000 | 2,175,000,000 | 2,088,000,000 | 2,076,000,000 | 2,003,000,000 | 2,190,000,000 | 2,111,000,000 | 1,637,000,000 | 1,986,000,000 | 2,198,000,000 | 2,180,000,000 | 2,122,000,000 | 1,989,000,000 | 2,098,000,000 | 2,108,000,000 | 2,100,000,000 | 1,965,000,000 | 2,133,000,000 | 2,186,000,000 | 2,200,000,000 | 2,076,000,000 | 597,175,000 | 2,388,700,000 | 2,336,100,000 | 2,748,200,000 | 2,695,000,000 | 2,022,900,000 | 1,851,100,000 | 2,031,532,000 | 1,506,421,000 | 1,063,513,000 | 1,038,867,000 | 946,669,000 | 856,892,000 | 748,742,000 | 204,291,000 | 187,716,000 | 165,393,000 | 171,438,000 | 170,530,000 | 175,666,000 | 196,914,000 | 193,957,000 | 178,321,000 | 190,766,000 | 1,021,278,000 | 238,002,000 | 1,024,085,000 | |||||||
other revenues | 24,000,000 | 28,000,000 | 24,000,000 | 26,000,000 | 32,000,000 | 31,000,000 | 28,000,000 | 24,000,000 | 24,000,000 | 26,000,000 | 25,000,000 | 21,000,000 | 22,000,000 | 18,000,000 | 20,000,000 | 20,000,000 | 20,000,000 | 21,000,000 | 23,000,000 | 24,000,000 | 24,000,000 | 23,000,000 | 27,000,000 | 27,000,000 | 26,000,000 | 26,000,000 | 29,000,000 | 30,000,000 | 27,000,000 | 23,000,000 | 28,000,000 | 28,000,000 | 30,000,000 | 30,000,000 | 33,000,000 | 33,000,000 | 33,000,000 | 7,875,000 | 31,500,000 | 35,500,000 | 38,600,000 | 37,400,000 | 33,300,000 | 35,100,000 | |||||||||||||||||||||||||||
revenues - sum | 2,524,000,000 | 2,796,000,000 | 2,681,000,000 | 2,530,000,000 | 2,259,000,000 | 2,559,000,000 | 2,510,000,000 | 2,403,000,000 | 2,153,000,000 | 2,408,000,000 | 2,238,000,000 | 2,167,000,000 | 1,944,000,000 | 1,967,000,000 | 2,027,000,000 | 1,453,500,000 | 2,138,000,000 | 2,224,000,000 | 2,209,000,000 | 2,152,000,000 | 2,016,000,000 | 2,109,000,000 | 640,083,250 | 884,140,000 | |||||||||||||||||||||||||||||||||||||||||||||||
expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of goods sold | 721,000,000 | 783,000,000 | 735,000,000 | 748,000,000 | 683,000,000 | 711,000,000 | 682,000,000 | 708,000,000 | 628,000,000 | 695,000,000 | 612,000,000 | 640,000,000 | 572,000,000 | 645,000,000 | 578,000,000 | 570,000,000 | 543,000,000 | 619,000,000 | 574,000,000 | 604,000,000 | 564,000,000 | 637,000,000 | 578,000,000 | 482,000,000 | 505,000,000 | 622,000,000 | 571,000,000 | 580,000,000 | 524,000,000 | 592,000,000 | 573,000,000 | 584,000,000 | 560,000,000 | 637,000,000 | 650,000,000 | 635,000,000 | 50,669,000 | 50,057,000 | 44,840,000 | 52,087,000 | 47,468,000 | 43,877,000 | 53,735,000 | 62,272,000 | 50,458,000 | 54,534,000 | 211,152,000 | 56,416,000 | 223,281,000 | ||||||||||||||||||||||
cost of other revenues | 17,000,000 | 15,000,000 | 15,000,000 | 16,000,000 | 18,000,000 | 16,000,000 | 14,000,000 | 11,000,000 | 12,000,000 | 10,000,000 | 11,000,000 | 9,000,000 | 10,000,000 | 7,000,000 | 6,000,000 | 7,000,000 | 8,000,000 | 7,000,000 | 8,000,000 | 8,000,000 | 10,000,000 | 8,000,000 | 12,000,000 | 13,000,000 | 14,000,000 | 13,000,000 | 13,000,000 | 14,000,000 | 13,000,000 | 10,000,000 | 9,000,000 | 10,000,000 | 13,000,000 | 10,000,000 | 9,000,000 | 11,000,000 | 12,000,000 | 2,625,000 | 10,500,000 | 9,700,000 | 13,600,000 | 15,200,000 | 15,000,000 | ||||||||||||||||||||||||||||
selling, general and administrative | 861,000,000 | 882,000,000 | 795,000,000 | 894,000,000 | 867,000,000 | 820,000,000 | 850,000,000 | 832,000,000 | 794,000,000 | 766,000,000 | 715,000,000 | 711,000,000 | 725,000,000 | 666,000,000 | 661,000,000 | 676,000,000 | 622,000,000 | 680,000,000 | 653,000,000 | 685,000,000 | 606,000,000 | 636,000,000 | 572,000,000 | 526,000,000 | 633,000,000 | 668,000,000 | 648,000,000 | 651,000,000 | 587,000,000 | 626,000,000 | 614,000,000 | 642,000,000 | 591,000,000 | 639,000,000 | 623,000,000 | 659,000,000 | 661,000,000 | 167,875,000 | 671,500,000 | 812,600,000 | 697,600,000 | 685,500,000 | 504,100,000 | 482,000,000 | 450,255,000 | 355,637,000 | 257,373,000 | 241,899,000 | 204,697,000 | 188,660,000 | 185,440,000 | 44,774,000 | 49,498,000 | 43,244,000 | 44,031,000 | 44,661,000 | 56,633,000 | 43,597,000 | 31,418,000 | 33,660,000 | 46,329,000 | 238,441,000 | 49,594,000 | 238,441,000 | |||||||
research and development | 163,000,000 | 161,000,000 | 166,000,000 | 159,000,000 | 143,000,000 | 163,000,000 | 146,000,000 | 156,000,000 | 151,000,000 | 152,000,000 | 153,000,000 | 156,000,000 | 143,000,000 | 142,000,000 | 133,000,000 | 127,000,000 | 127,000,000 | 117,000,000 | 121,000,000 | 115,000,000 | 112,000,000 | 119,000,000 | 103,000,000 | 108,000,000 | 122,000,000 | 114,000,000 | 123,000,000 | 117,000,000 | 117,000,000 | 120,000,000 | 107,000,000 | 94,000,000 | 92,000,000 | 90,000,000 | 81,000,000 | 94,000,000 | 96,000,000 | 31,075,000 | 124,300,000 | 103,100,000 | 101,600,000 | 81,100,000 | 59,100,000 | 61,300,000 | 59,510,000 | 49,009,000 | 24,469,000 | 23,795,000 | 20,165,000 | 19,170,000 | 17,711,000 | 3,392,000 | 3,255,000 | 3,715,000 | 5,834,000 | 5,465,000 | 5,704,000 | 7,353,000 | 5,372,000 | 6,237,000 | 7,378,000 | 21,593,000 | 4,841,000 | 21,593,000 | |||||||
amortization of intangible assets | 241,000,000 | 236,000,000 | 253,000,000 | 256,000,000 | 256,000,000 | 259,000,000 | 274,000,000 | 270,000,000 | 274,000,000 | 282,000,000 | 253,000,000 | 269,000,000 | 273,000,000 | 313,000,000 | 290,000,000 | 302,000,000 | 310,000,000 | 320,000,000 | 338,000,000 | 360,000,000 | 357,000,000 | 382,000,000 | 391,000,000 | 436,000,000 | 436,000,000 | 445,000,000 | 475,000,000 | 488,000,000 | 489,000,000 | 502,000,000 | 658,000,000 | 741,000,000 | 743,000,000 | 775,000,000 | 657,000,000 | 623,000,000 | 635,000,000 | 303,598,000 | 326,175,000 | 299,485,000 | 218,187,000 | 210,570,000 | 33,121,000 | 21,778,000 | 15,503,000 | 15,642,000 | 12,342,000 | ||||||||||||||||||||||||
goodwill impairments | 1,426,000,000 | 91,000,000 | 402,000,000 | 622,000,000 | 119,000,000 | 83,000,000 | 469,000,000 | 109,000,000 | 2,213,000,000 | 312,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restructuring, integration and separation costs | 13,000,000 | 28,000,000 | 17,000,000 | 31,000,000 | 1,000,000 | 6,250,000 | 1,000,000 | 12,000,000 | 12,000,000 | 9,000,000 | 12,000,000 | 9,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other expense | 32,000,000 | 65,000,000 | 80,000,000 | -18,000,000 | 15,000,000 | 2,000,000 | 225,000,000 | 20,000,000 | 60,000,000 | -83,000,000 | 23,000,000 | 29,000,000 | 4,000,000 | 2,000,000 | 44,000,000 | -183,000,000 | 542,000,000 | -30,000,000 | 308,000,000 | 16,000,000 | 107,000,000 | 23,000,000 | 1,399,000,000 | 10,000,000 | 8,000,000 | -4,000,000 | 11,000,000 | 231,000,000 | -325,000,000 | -240,000,000 | -232,000,000 | ||||||||||||||||||||||||||||||||||||||||
expenses - sum | 3,474,000,000 | 2,322,000,000 | 2,062,000,000 | 2,086,000,000 | 1,983,000,000 | 2,001,000,000 | 2,192,000,000 | 2,014,000,000 | 1,872,000,000 | 2,046,000,000 | 2,224,000,000 | 1,755,000,000 | 1,769,000,000 | 1,806,000,000 | 2,248,000,000 | 1,283,250,000 | 1,678,000,000 | 3,300,000,000 | 1,880,000,000 | 1,895,000,000 | 1,729,000,000 | 119,704,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
operating income | -950,000,000 | 474,000,000 | 619,000,000 | 444,000,000 | 276,000,000 | 558,000,000 | 318,000,000 | 389,000,000 | 281,000,000 | 362,000,000 | 14,000,000 | 412,000,000 | 175,000,000 | -236,000,000 | 244,000,000 | 161,000,000 | 285,000,000 | 367,000,000 | 574,000,000 | -270,000,000 | -221,000,000 | -5,000,000 | 460,000,000 | -27,000,000 | 248,000,000 | -1,076,000,000 | 329,000,000 | 257,000,000 | 287,000,000 | 25,000,000 | 117,000,000 | -245,000,000 | -2,281,000,000 | -322,000,000 | 38,000,000 | 175,000,000 | 211,000,000 | -646,500,000 | 80,500,000 | 66,200,000 | 447,800,000 | 341,500,000 | 683,900,000 | 356,600,000 | 223,477,000 | -891,498,000 | 141,513,000 | 117,006,000 | -98,085,000 | 29,464,000 | 86,810,000 | 58,344,000 | 10,547,000 | 53,615,000 | 36,879,000 | 48,363,000 | 63,140,000 | 61,000,000 | 62,460,000 | 238,867,000 | 98,647,000 | 229,545,000 | |||||||||
yoy | -444.20% | -15.05% | 94.65% | 14.14% | -1.78% | 54.14% | 2171.43% | -5.58% | 60.57% | -253.39% | -94.26% | 155.90% | -38.60% | -164.31% | -57.49% | -159.63% | -228.96% | -7440.00% | 24.78% | 900.00% | -189.11% | -99.54% | 39.82% | -110.51% | -13.59% | -4404.00% | 181.20% | -204.90% | -112.58% | -107.76% | 207.89% | -240.00% | -1181.04% | -50.19% | -52.80% | 164.35% | -52.88% | -289.31% | -88.23% | -81.44% | 100.38% | -138.31% | 383.28% | 204.77% | -327.84% | -3125.72% | 63.01% | 100.55% | -1029.98% | -45.05% | 135.39% | 20.64% | -23.40% | 3.51% | 4.06% | ||||||||||||||||
qoq | -300.42% | -23.42% | 39.41% | 60.87% | -50.54% | 75.47% | -18.25% | 38.43% | -22.38% | 2485.71% | -96.60% | 135.43% | -174.15% | -196.72% | 51.55% | -43.51% | -22.34% | -36.06% | -312.59% | 22.17% | 4320.00% | -101.09% | -1803.70% | -110.89% | -123.05% | -427.05% | 28.02% | -10.45% | 1048.00% | -78.63% | -147.76% | -89.26% | 608.39% | -947.37% | -78.29% | -17.06% | -132.64% | -903.11% | 21.60% | -85.22% | 31.13% | -50.07% | 91.78% | 59.57% | -125.07% | -729.98% | 20.95% | -219.29% | -432.90% | -66.06% | 48.79% | 453.18% | -80.33% | 45.38% | -23.75% | -2.34% | -73.85% | 142.14% | |||||||||||||
operating margin % | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | Infinity% | Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | NaN% | NaN% | NaN% | Infinity% | NaN% | NaN% | NaN% | Infinity% | Infinity% | Infinity% | Infinity% | NaN% | NaN% | Infinity% | |
interest income | 10,000,000 | 9,000,000 | 15,000,000 | 13,000,000 | 11,000,000 | 9,000,000 | 7,000,000 | 8,000,000 | 9,000,000 | 7,000,000 | 6,000,000 | 7,000,000 | 6,000,000 | 6,000,000 | 3,000,000 | 3,000,000 | 2,000,000 | 1,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 7,000,000 | 3,000,000 | 2,000,000 | 3,000,000 | 4,000,000 | 2,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 525,000 | 2,100,000 | 900,000 | 700,000 | 900,000 | 800,000 | 1,800,000 | 2,687,000 | 2,686,000 | 1,054,000 | 1,596,000 | 2,687,000 | 1,156,000 | 1,020,000 | 238,000 | 251,000 | 334,000 | 737,000 | 1,783,000 | 3,412,000 | 3,468,000 | 4,943,000 | 3,789,000 | 6,070,000 | 29,199,000 | 9,761,000 | 29,199,000 | |||||||
interest expense | -402,000,000 | -397,000,000 | -412,000,000 | -465,000,000 | -330,000,000 | -337,000,000 | -346,000,000 | -350,000,000 | -355,000,000 | -363,000,000 | -339,000,000 | -319,000,000 | -307,000,000 | -307,000,000 | -385,000,000 | -410,000,000 | -362,000,000 | -343,000,000 | -351,000,000 | -364,000,000 | -368,000,000 | -379,000,000 | -374,000,000 | -385,000,000 | -396,000,000 | -391,000,000 | -406,000,000 | -409,000,000 | -406,000,000 | -414,000,000 | -420,000,000 | -435,000,000 | -416,000,000 | -448,000,000 | -459,000,000 | -459,000,000 | -474,000,000 | -118,125,000 | -472,500,000 | -426,600,000 | -420,200,000 | -412,700,000 | -258,400,000 | -246,500,000 | -262,902,000 | -249,306,000 | -176,793,000 | -155,315,000 | -154,715,000 | -116,042,000 | -100,614,000 | -4,049,000 | |||||||||||||||||||
loss on extinguishment of debt | -1,000,000 | -12,000,000 | -45,000,000 | -5,000,000 | -8,000,000 | -27,000,000 | -24,000,000 | -2,000,000 | -33,000,000 | -7,000,000 | -44,000,000 | -48,000,000 | -27,000,000 | -57,000,000 | -1,000,000 | -64,000,000 | -93,700,000 | -35,474,000 | -8,161,000 | -21,379,000 | -17,625,000 | -2,322,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange and other | -11,000,000 | -11,000,000 | -7,000,000 | -30,000,000 | -4,000,000 | -21,000,000 | -11,000,000 | -15,000,000 | -14,000,000 | -7,000,000 | -21,000,000 | -10,000,000 | -12,000,000 | 7,000,000 | 4,000,000 | -7,000,000 | -4,000,000 | 3,000,000 | 7,000,000 | 1,000,000 | -4,000,000 | -13,000,000 | -13,000,000 | -4,000,000 | 9,000,000 | 3,000,000 | 5,000,000 | -9,000,000 | 27,000,000 | 20,000,000 | 19,000,000 | 39,000,000 | 29,000,000 | 3,275,000 | 13,100,000 | -6,200,000 | -34,000,000 | 5,600,000 | -53,000,000 | -13,400,000 | -5,901,000 | 5,079,000 | -10,082,000 | 1,439,000 | 1,263,000 | -1,603,000 | -4,238,000 | ||||||||||||||||||||||||
income before income taxes | -1,354,000,000 | 56,000,000 | 218,000,000 | 140,000,000 | -47,000,000 | 209,000,000 | -21,000,000 | 48,000,000 | -69,000,000 | -7,000,000 | -326,000,000 | 79,000,000 | -136,000,000 | -357,000,000 | 439,000,000 | -129,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
provision for income taxes | -77,000,000 | -159,000,000 | -37,000,000 | -12,000,000 | -39,000,000 | -111,000,000 | -71,000,000 | -49,000,000 | -8,000,000 | -45,250,000 | -56,000,000 | 12,300,000 | 4,600,000 | 5,600,000 | 5,400,000 | 700,000 | 3,500,000 | 14,500,000 | 5,200,000 | 14,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
net income | -1,431,000,000 | -103,000,000 | 181,000,000 | 128,000,000 | -86,000,000 | 98,000,000 | -92,000,000 | -1,000,000 | -77,000,000 | -47,000,000 | -382,000,000 | 27,000,000 | -209,000,000 | -410,000,000 | 403,000,000 | -139,000,000 | -66,000,000 | 72,000,000 | 191,000,000 | -593,000,000 | -607,000,000 | -152,000,000 | 70,000,000 | -325,000,000 | -152,000,000 | -1,517,000,000 | -48,000,000 | -170,000,000 | -48,000,000 | -342,000,000 | -351,000,000 | -872,000,000 | -2,691,000,000 | 512,000,000 | 1,300,000,000 | -37,000,000 | 629,000,000 | -2,104,000,000 | -304,000,000 | -372,900,000 | 51,700,000 | -51,600,000 | 276,400,000 | -20,300,000 | 124,970,000 | -971,975,000 | 10,866,000 | -27,530,000 | -89,142,000 | 7,645,000 | -21,607,000 | 40,362,000 | 24,090,000 | 39,003,000 | 120,380,000 | 48,437,000 | -25,289,000 | 56,376,000 | -31,971,000 | 65,867,000 | 67,824,000 | 211,626,000 | 93,819,000 | 203,948,000 | |||||||
yoy | 1563.95% | -205.10% | -296.74% | -12900.00% | 11.69% | -308.51% | -75.92% | -103.70% | -63.16% | -88.54% | -194.79% | -119.42% | 216.67% | -669.44% | 110.99% | -76.56% | -89.13% | -147.37% | 172.86% | 82.46% | 299.34% | -89.98% | -245.83% | 91.18% | 216.67% | 343.57% | -86.32% | -80.50% | -98.22% | -166.80% | -127.00% | 2256.76% | -527.82% | -124.33% | -527.63% | -90.08% | 1116.63% | 3977.52% | -209.99% | 1736.95% | -58.63% | -94.69% | 2443.71% | -26.26% | -240.19% | -12813.87% | -150.29% | -168.21% | -470.04% | -80.40% | -117.95% | -16.67% | -195.26% | -14.08% | -20.90% | -14.41% | -147.14% | 3.76% | |||||||||||||
qoq | 1289.32% | -156.91% | 41.41% | -248.84% | -187.76% | -206.52% | 9100.00% | -98.70% | 63.83% | -87.70% | -1514.81% | -112.92% | -49.02% | -201.74% | -389.93% | 110.61% | -191.67% | -62.30% | -132.21% | -2.31% | 299.34% | -317.14% | -121.54% | 113.82% | -89.98% | 3060.42% | -71.76% | 254.17% | -85.96% | -2.56% | -59.75% | -67.60% | -625.59% | -60.62% | -3613.51% | -105.88% | -129.90% | 592.11% | -18.48% | -821.28% | -200.19% | -118.67% | -1461.58% | -116.24% | -112.86% | -9045.10% | -139.47% | -69.12% | -1266.02% | -135.38% | -153.53% | 67.55% | -38.24% | -67.60% | 148.53% | -291.53% | -276.33% | -2.89% | -67.95% | 125.57% | |||||||||||
net income margin % | -Infinity% | -Infinity% | Infinity% | Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | Infinity% | -Infinity% | Infinity% | -Infinity% | Infinity% | -Infinity% | -Infinity% | Infinity% | -Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | -Infinity% | NaN% | NaN% | Infinity% | -Infinity% | NaN% | NaN% | Infinity% | Infinity% | Infinity% | Infinity% | NaN% | NaN% | Infinity% | |
net loss attributable to noncontrolling interest | 8,000,000 | -9,000,000 | -2,000,000 | 20,000,000 | 28,000,000 | -5,000,000 | 7,000,000 | 11,000,000 | 13,000,000 | 8,000,000 | 4,000,000 | -1,000,000 | 8,000,000 | -2,000,000 | -3,000,000 | 1,000,000 | -1,500,000 | -1,000,000 | -500,000 | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
net loss attributable to bausch health companies inc. | -1,423,000,000 | -58,000,000 | 93,000,000 | -85,000,000 | -64,000,000 | -201,000,000 | -145,000,000 | -69,000,000 | -595,000,000 | -610,000,000 | -326,000,000 | -152,000,000 | -68,000,000 | -49,000,000 | -171,000,000 | -52,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted loss per share attributable to bausch health companies inc. | -3.82 | -0.16 | 0.25 | -0.23 | -0.17 | -0.55 | -0.4 | -0.19 | -1.66 | -1.71 | -0.92 | -0.43 | -0.193 | -0.14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted weighted-average common shares | 372.8 | 369.6 | 368 | 368.4 | 366.8 | 364.9 | 363.3 | 362 | 362.2 | 360.8 | 358.9 | 359.1 | 356.8 | 355 | 355.3 | 353.4 | 352.4 | 352.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
asset impairments | 7,000,000 | 1,000,000 | 23,000,000 | 5,000,000 | 1,000,000 | 13,500,000 | 4,000,000 | 37,000,000 | 13,000,000 | 4,250,000 | 2,000,000 | 1,000,000 | 14,000,000 | 26,000,000 | 33,000,000 | 13,000,000 | 3,000,000 | 134,000,000 | 89,000,000 | 301,000,000 | 44,000,000 | 85,000,000 | 406,000,000 | 85,000,000 | 138,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
gain on extinguishment of debt | -19,000,000 | 3,000,000 | 178,000,000 | 12,000,000 | 11,000,000 | 192,000,000 | 570,000,000 | 113,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to bausch health companies inc. | -112,000,000 | 179,000,000 | 148,000,000 | 10,000,000 | -138,250,000 | -378,000,000 | 26,000,000 | 46,250,000 | 399,000,000 | -254,250,000 | 188,000,000 | -101,750,000 | 71,000,000 | -344,000,000 | -350,000,000 | -873,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share attributable to bausch health companies inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | -0.31 | 0.48 | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.46 | 3.71 | -0.11 | 1.8 | -6.06 | -0.88 | -1.08 | 0.14 | -0.15 | 0.82 | 0.43 | -2.92 | ||||||||||||||||||||||||||||||||||||||||||
diluted | -0.3 | 0.48 | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.45 | 3.69 | -0.11 | 1.79 | -6.06 | -0.88 | -1.08 | 0.14 | -0.15 | 0.81 | 0.43 | -2.92 | ||||||||||||||||||||||||||||||||||||||||||
weighted-average common shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 370.9 | 371.3 | 370.9 | 367.9 | 365.4 | 364.8 | 362.5 | 359.6 | 355.6 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 350.2 | 350.4 | 350.1 | 349.8 | 345 | 344.9 | 344.9 | 344.4 | 335.4 | 320,996 | 333,643 | 308,153 | 305,446 | 304,075 | 304,816 | 158,231 | 158,224 | 158,218 | 158,495 | 158,715 | 160,709 | 161,024 | 161,020 | 160,847 | 160,060 | 160,060 | ||||||||||||||||||||||||||||||
diluted | 375 | 375.5 | 373.1 | 370.2 | 365.4 | 367.1 | 363.4 | 364 | 357.8 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 351.8 | 352.3 | 350.1 | 350.5 | 345 | 344.9 | 351 | 344.4 | 341.3 | 320,996 | 333,643 | 314,447 | 305,446 | 311,743 | 304,816 | 158,652 | 158,331 | 158,270 | 158,495 | 158,715 | 160,709 | 161,024 | 161,020 | 160,988 | 160,078 | 160,078 | ||||||||||||||||||||||||||||||
restructuring, integration, separation and ipo costs | 22,000,000 | 14,000,000 | 16,000,000 | 10,000,000 | 5,000,000 | 10,000,000 | 35,000,000 | 13,000,000 | 21,000,000 | 8,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
benefit from income taxes | -52,000,000 | -73,000,000 | -53,000,000 | -36,000,000 | -10,000,000 | 16,000,000 | 51,000,000 | -25,000,000 | 77,000,000 | -16,000,000 | 242,000,000 | -5,000,000 | 112,000,000 | 26,000,000 | -47,000,000 | 18,000,000 | 9,000,000 | 74,000,000 | 84,000,000 | -51,000,000 | -138,000,000 | -3,000,000 | 7,200,000 | 7,500,000 | 3,700,000 | 3,800,000 | |||||||||||||||||||||||||||||||||||||||||||||
asset impairments, including loss on assets held for sale | 1,000,000 | 6,000,000 | 8,000,000 | 21,000,000 | 18,000,000 | 47,000,000 | 148,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to noncontrolling interest | -4,000,000 | -6,000,000 | -3,000,000 | -2,000,000 | -3,000,000 | -1,000,000 | -1,000,000 | -4,000,000 | -1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before provision for income taxes | -82,000,000 | 51,303,000 | 53,037,000 | 61,776,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before benefit from income taxes | -261,250,000 | 216,000,000 | -135,000,000 | 75,000,000 | -365,700,000 | 47,862,000 | 27,790,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss before benefit from income taxes | -670,000,000 | -591,000,000 | -437,000,000 | -178,000,000 | -1,470,000,000 | -66,000,000 | -179,000,000 | -122,000,000 | -426,000,000 | -300,000,000 | -734,000,000 | -2,694,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition-related contingent consideration | 22,000,000 | 2,000,000 | 11,000,000 | 13,000,000 | 10,000,000 | 3,000,000 | 20,000,000 | -21,000,000 | 14,000,000 | -19,000,000 | -6,000,000 | 2,000,000 | 8,000,000 | -238,000,000 | -49,000,000 | -10,000,000 | 1,725,000 | 6,900,000 | 2,400,000 | 3,800,000 | 11,700,000 | 4,000,000 | 8,900,000 | 4,252,000 | -34,995,000 | 3,669,000 | -2,185,000 | -28,464,000 | 5,630,000 | 7,729,000 | |||||||||||||||||||||||||||||||||||||||||
restructuring and integration costs | 7,000,000 | 4,000,000 | 3,000,000 | 4,000,000 | 4,000,000 | 20,000,000 | 6,000,000 | 3,000,000 | 7,000,000 | 6,000,000 | 10,000,000 | 6,000,000 | 18,000,000 | 18,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted loss per share attributable to bausch health companies inc.: | -0.49 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired in-process research and development costs | 1,000,000 | 1,000,000 | 1,000,000 | 4,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss per share attributable to bausch health companies inc.: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | -0.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | -0.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other income | -1,000,000 | -15,000,000 | -19,000,000 | -11,325,000 | -45,300,000 | 23,100,000 | 30,200,000 | 176,900,000 | -43,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share attributable to bausch health companies inc.: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | -0.31 | 0.48 | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.46 | 3.71 | -0.11 | 1.8 | -6.06 | -0.88 | -1.08 | 0.14 | -0.15 | 0.82 | 0.43 | -2.92 | ||||||||||||||||||||||||||||||||||||||||||
diluted | -0.3 | 0.48 | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.45 | 3.69 | -0.11 | 1.79 | -6.06 | -0.88 | -1.08 | 0.14 | -0.15 | 0.81 | 0.43 | -2.92 | ||||||||||||||||||||||||||||||||||||||||||
less: net income attributable to noncontrolling interest | 2,000,000 | 250,000 | -1,000,000 | 1,000,000 | 1,000,000 | -425,000 | -1,700,000 | 800,000 | 2,200,000 | 1,400,000 | 1,000,000 | 2,300,000 | 1,205,000 | 1,268,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to valeant pharmaceuticals international, inc. | -2,693,000,000 | 513,000,000 | 1,301,000,000 | -38,000,000 | 628,000,000 | -2,106,700,000 | -302,300,000 | -373,700,000 | 49,500,000 | -53,000,000 | 275,400,000 | -22,600,000 | 123,765,000 | -973,243,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share attributable to valeant pharmaceuticals international, inc.: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | -0.31 | 0.48 | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.46 | 3.71 | -0.11 | 1.8 | -6.06 | -0.88 | -1.08 | 0.14 | -0.15 | 0.82 | 0.43 | -2.92 | ||||||||||||||||||||||||||||||||||||||||||
diluted | -0.3 | 0.48 | 0.4 | 0.03 | -0.38 | -1.03 | 0.07 | 0.128 | 1.1 | -0.71 | 0.52 | -0.288 | 0.2 | -0.98 | -1 | -2.49 | -7.68 | 1.45 | 3.69 | -0.11 | 1.79 | -6.06 | -0.88 | -1.08 | 0.14 | -0.15 | 0.81 | 0.43 | -2.92 | ||||||||||||||||||||||||||||||||||||||||||
loss before recovery of income taxes | -234,250,000 | -400,000,000 | -242,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
recovery of income taxes | -707,250,000 | -1,700,000,000 | -205,000,000 | -203,083,000 | -169,225,000 | -27,264,000 | -185,501,000 | -96,992,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of goods sold (excluding amortization and impairments of | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible assets) | 584,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of goods sold (excluding amortization and impairments of - sum | 1,898,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss before (recovery of) provision for income taxes | -295,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(recovery of) provision for income taxes | -924,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of goods sold (exclusive of amortization and impairments of | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
finite-lived intangible assets shown separately below) | 161,825,000 | 647,300,000 | 620,200,000 | 634,600,000 | 669,900,000 | 545,800,000 | 504,100,000 | 282,235,500 | 560,855,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization and impairments of finite-lived intangible assets | 221,900,000 | 887,600,000 | 694,500,000 | 679,200,000 | 585,400,000 | 393,100,000 | 355,200,000 | 361,956,000 | 910,248,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restructuring, integration and other costs | 4,875,000 | 19,500,000 | 38,000,000 | 75,600,000 | 143,400,000 | 61,700,000 | 133,600,000 | 116,285,000 | 295,890,000 | 53,665,000 | 48,985,000 | 209,174,000 | 42,872,000 | 30,004,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
in-process research and development impairments and other charges | 4,350,000 | 17,400,000 | 95,800,000 | 12,300,000 | 19,900,000 | 12,000,000 | 24,828,000 | 123,981,000 | 4,830,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition-related costs | 1,800,000 | 7,000,000 | 9,500,000 | 1,600,000 | 1,500,000 | 11,988,000 | 8,650,000 | 7,879,000 | 7,899,000 | 52,627,000 | 4,605,000 | 13,867,000 | 5,596,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before (recovery of) benefit from income taxes | -94,200,000 | -376,800,000 | -5,700,000 | -64,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(recovery of) benefit from income taxes | -18,200,000 | -72,800,000 | -57,400,000 | -13,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average common shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 370.9 | 371.3 | 370.9 | 367.9 | 365.4 | 364.8 | 362.5 | 359.6 | 355.6 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 350.2 | 350.4 | 350.1 | 349.8 | 345 | 344.9 | 344.9 | 344.4 | 335.4 | 320,996 | 333,643 | 308,153 | 305,446 | 304,075 | 304,816 | 158,231 | 158,224 | 158,218 | 158,495 | 158,715 | 160,709 | 161,024 | 161,020 | 160,847 | 160,060 | 160,060 | ||||||||||||||||||||||||||||||
diluted | 375 | 375.5 | 373.1 | 370.2 | 365.4 | 367.1 | 363.4 | 364 | 357.8 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 351.8 | 352.3 | 350.1 | 350.5 | 345 | 344.9 | 351 | 344.4 | 341.3 | 320,996 | 333,643 | 314,447 | 305,446 | 311,743 | 304,816 | 158,652 | 158,331 | 158,270 | 158,495 | 158,715 | 160,709 | 161,024 | 161,020 | 160,988 | 160,078 | 160,078 | ||||||||||||||||||||||||||||||
gain on investments | 3,400,000 | 3,963,000 | 1,859,000 | 32,000 | -35,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before provision for (recovery of) income taxes | 376,700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
provision for (recovery of) income taxes | 100,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of alliance and service revenues | 14,300,000 | 14,565,000 | 14,353,000 | 14,459,000 | 15,429,000 | 11,523,000 | 10,582,000 | 12,483,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before benefit from (recovery of) income taxes | 4,800,000 | -17,057,000 | 31,780,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
benefit from (recovery of) income taxes | 25,100,000 | 4,550,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss per share attributable to valeant pharmaceuticals international, inc.: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | -0.07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average common shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | 334.9 | 305,763 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
alliance and royalty | 12,955,000 | 16,471,000 | 13,922,000 | 9,258,000 | 23,493,000 | 12,248,000 | 56,869,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
service and other | 19,270,000 | 18,839,000 | 18,327,000 | 20,230,000 | 16,131,000 | 15,000,000 | 14,479,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
legal settlements and related fees | 38,793,250 | 149,601,000 | 1,124,000 | 4,448,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before recovery of income taxes | -78,113,000 | -1,141,200,000 | -54,794,000 | -29,896,250 | -89,347,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of goods sold (exclusive of amortization of | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible assets shown separately below) | 283,183,000 | 284,904,000 | 161,598,750 | 219,670,000 | 197,284,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before (recovery of ) benefit from income taxes | -40,345,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(recovery of ) benefit from income taxes | -51,211,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic earnings per share | 0.04 | -0.29 | 0.03 | -0.07 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per share | 0.03 | -0.29 | 0.02 | -0.07 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted loss per share | -0.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired in-process research and development | 37,467,000 | 145,300,000 | 4,568,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
legal settlements | 53,624,000 | 241,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of goods sold (exclusive of amortization of - sum | 595,640,750 | 854,676,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
revenue | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
yoy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
qoq | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
royalty and other | 4,840,000 | 2,564,000 | 4,211,000 | 4,224,000 | 5,094,000 | 4,725,000 | 4,231,000 | 4,567,000 | 4,332,000 | 4,883,000 | 24,851,000 | 4,162,000 | 24,851,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restructuring costs | 2,413,000 | 11,367,000 | 1,348,000 | 10,855,000 | 7,587,000 | 51,760,000 | 887,000 | 15,126,000 | 645,000 | 15,126,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange gain | 197,000 | 314,000 | 407,000 | 82,000 | 204,000 | 221,000 | 5,255,000 | 763,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on auction rate security settlement | 22,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of investments | 466,000 | 344,000 | 4,156,000 | 3,461,000 | 8,640,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment loss on debt securities | -1,617,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment loss on equity securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity loss | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted earnings per share | 0.25 | 0.15 | 0.25 | 0.76 | 0.31 | -0.16 | 0.35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average number of common shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 370.9 | 371.3 | 370.9 | 367.9 | 365.4 | 364.8 | 362.5 | 359.6 | 355.6 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 350.2 | 350.4 | 350.1 | 349.8 | 345 | 344.9 | 344.9 | 344.4 | 335.4 | 320,996 | 333,643 | 308,153 | 305,446 | 304,075 | 304,816 | 158,231 | 158,224 | 158,218 | 158,495 | 158,715 | 160,709 | 161,024 | 161,020 | 160,847 | 160,060 | 160,060 | ||||||||||||||||||||||||||||||
diluted | 375 | 375.5 | 373.1 | 370.2 | 365.4 | 367.1 | 363.4 | 364 | 357.8 | 352.1 | 351.3 | 351.3 | 351.5 | 351.3 | 350.7 | 351.8 | 352.3 | 350.1 | 350.5 | 345 | 344.9 | 351 | 344.4 | 341.3 | 320,996 | 333,643 | 314,447 | 305,446 | 311,743 | 304,816 | 158,652 | 158,331 | 158,270 | 158,495 | 158,715 | 160,709 | 161,024 | 161,020 | 160,988 | 160,078 | 160,078 | ||||||||||||||||||||||||||||||
cash dividends declared per share | 0.09 | 0.09 | 0.375 | 0.375 | 0.375 | 0.375 | 0.375 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
revenue - sum | 173,319,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on impairment of investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of investment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
legal settlements, net of insurance recoveries | 5,917,000 | 93,052,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible asset impairments, net of gain on disposal | 9,910,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contract recoveries | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on early extinguishment of debt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization | 11,691,000 | 11,694,000 | 12,107,000 | 11,979,000 | 11,982,000 | 56,457,000 | 11,981,000 | 56,457,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
legal settlement | 24,648,000 | 2,062,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted weighted-average number of common shares outstanding | 161,024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contract costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from continuing operations before provision for income taxes | 69,367,000 | 229,974,000 | 99,019,000 | 222,296,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from continuing operations | -0.2 | 65,867,000 | 67,824,000 | 215,474,000 | 93,819,000 | 207,796,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss from discontinued operation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
asset impairments, net of gain on disposal | 143,000,000 | 143,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of investment | 15,716,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity income | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from continuing operations before benefit from income taxes | 71,624,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from discontinued operation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contract losses | 54,800,000 | 54,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
litigation settlements | 14,400,000 | 14,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired research and development | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity loss and other | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange loss | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted average number of common shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 160,559 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 160,559 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2009-09-30 | 2009-06-30 | 2008-12-31 | 2008-11-06 | 2008-08-13 | 2008-05-08 | 2008-03-31 | 2008-03-17 | 2007-12-31 | 2007-11-08 | 2007-09-30 | 2007-06-30 | 2007-05-31 | 2007-05-18 | 2007-03-31 | 2007-03-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 1,299,000,000 | 1,309,000,000 | 1,308,000,000 | 1,727,000,000 | 1,134,000,000 | 1,181,000,000 | 719,000,000 | 595,000,000 | 733,000,000 | 947,000,000 | 760,000,000 | 579,000,000 | 518,000,000 | 564,000,000 | 486,000,000 | 659,000,000 | 1,249,000,000 | 582,000,000 | 690,000,000 | 642,000,000 | 679,000,000 | 605,000,000 | 977,000,000 | 896,000,000 | 912,000,000 | 3,243,000,000 | 825,000,000 | 878,000,000 | 782,000,000 | 721,000,000 | 973,000,000 | 838,000,000 | 909,000,000 | 720,000,000 | 964,000,000 | 1,214,000,000 | 1,210,000,000 | 542,000,000 | 852,400,000 | 1,310,400,000 | 1,420,000,000 | 958,000,000 | 600,340,000 | 596,347,000 | 2,539,390,000 | 413,736,000 | 916,091,000 | 257,730,000 | 395,266,000 | 49,406,000 | 52,918,000 | 317,547,000 | 219,005,000 | 354,056,000 | 431,537,000 | 431,537,000 | 433,641,000 | 433,641,000 | 411,906,000 | 411,906,000 | 469,458,000 | 870,175,000 | 870,175,000 | ||
restricted cash | 13,000,000 | 16,000,000 | 32,000,000 | 16,000,000 | 23,000,000 | 20,000,000 | 31,000,000 | 28,000,000 | 22,000,000 | 20,000,000 | 9,000,000 | 13,000,000 | 1,214,000,000 | 1,214,000,000 | 1,214,000,000 | 1,211,000,000 | 1,011,000,000 | 1,011,000,000 | 1,011,000,000 | 1,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 2,000,000 | 77,000,000 | 928,000,000 | 811,000,000 | 8,231,000 | 8,598,000 | 5,250,000 | 5,250,000 | ||||||||||||||||||||||||||||||||||
trade receivables | 2,191,000,000 | 2,351,000,000 | 2,417,000,000 | 2,210,000,000 | 2,072,000,000 | 2,140,000,000 | 2,094,000,000 | 2,102,000,000 | 2,048,000,000 | 1,998,000,000 | 1,948,000,000 | 1,743,000,000 | 1,688,000,000 | 1,790,000,000 | 1,739,000,000 | 1,645,000,000 | 1,566,000,000 | 1,775,000,000 | 1,730,000,000 | 1,609,000,000 | 1,499,000,000 | 1,577,000,000 | 1,733,000,000 | 1,369,000,000 | 1,712,000,000 | 1,839,000,000 | 1,747,000,000 | 1,829,000,000 | 1,786,000,000 | 1,865,000,000 | 2,041,000,000 | 1,973,000,000 | 1,940,000,000 | 2,130,000,000 | 2,229,000,000 | 2,096,000,000 | 2,097,000,000 | 2,517,000,000 | 2,732,500,000 | 2,692,700,000 | 2,696,300,000 | 2,371,000,000 | |||||||||||||||||||||||
inventories | 1,601,000,000 | 1,629,000,000 | 1,598,000,000 | 1,655,000,000 | 1,613,000,000 | 1,595,000,000 | 1,655,000,000 | 1,612,000,000 | 1,636,000,000 | 1,544,000,000 | 1,272,000,000 | 1,240,000,000 | 1,222,000,000 | 1,090,000,000 | 1,056,000,000 | 1,073,000,000 | 1,045,000,000 | 993,000,000 | 1,058,000,000 | 1,086,000,000 | 1,076,000,000 | 1,094,000,000 | 1,224,000,000 | 1,226,000,000 | 1,124,000,000 | 1,107,000,000 | 1,100,000,000 | 1,060,000,000 | 1,012,000,000 | 934,000,000 | 971,000,000 | 993,000,000 | 1,042,000,000 | 1,048,000,000 | 1,071,000,000 | 1,084,000,000 | 1,111,000,000 | 1,061,000,000 | 1,336,700,000 | 1,320,200,000 | 1,199,200,000 | 1,229,500,000 | 882,966,000 | 1,076,088,000 | 497,059,000 | 509,676,000 | 531,256,000 | 418,252,000 | 388,729,000 | ||||||||||||||||
prepaid expenses and other current assets | 874,000,000 | 852,000,000 | 894,000,000 | 906,000,000 | 890,000,000 | 838,000,000 | 852,000,000 | 874,000,000 | 957,000,000 | 1,092,000,000 | 1,048,000,000 | 890,000,000 | 796,000,000 | 776,000,000 | 718,000,000 | 820,000,000 | 765,000,000 | 720,000,000 | 632,000,000 | 899,000,000 | 924,000,000 | 855,000,000 | 726,000,000 | 776,000,000 | 745,000,000 | 779,000,000 | 631,000,000 | 698,000,000 | 693,000,000 | 689,000,000 | 757,000,000 | 835,000,000 | 833,000,000 | 771,000,000 | 736,000,000 | 710,000,000 | 675,000,000 | 696,000,000 | 896,800,000 | 910,400,000 | 953,000,000 | 1,075,300,000 | 204,958,000 | 257,389,000 | 115,497,000 | 136,747,000 | 125,869,000 | 72,214,000 | 56,470,000 | ||||||||||||||||
total current assets | 5,978,000,000 | 6,157,000,000 | 6,249,000,000 | 6,514,000,000 | 5,732,000,000 | 5,774,000,000 | 5,351,000,000 | 5,211,000,000 | 5,396,000,000 | 5,596,000,000 | 5,048,000,000 | 4,461,000,000 | 4,237,000,000 | 4,247,000,000 | 4,010,000,000 | 5,417,000,000 | 5,836,000,000 | 5,607,000,000 | 5,324,000,000 | 5,450,000,000 | 5,392,000,000 | 5,342,000,000 | 5,671,000,000 | 5,278,000,000 | 5,504,000,000 | 6,969,000,000 | 4,305,000,000 | 4,467,000,000 | 4,275,000,000 | 4,211,000,000 | 4,742,000,000 | 4,639,000,000 | 4,724,000,000 | 4,746,000,000 | 5,944,000,000 | 5,992,000,000 | 5,333,000,000 | 5,077,000,000 | 5,818,400,000 | 6,233,700,000 | 6,995,700,000 | 6,345,200,000 | 3,885,889,000 | 3,848,363,000 | 4,532,026,000 | 2,370,129,000 | 2,777,451,000 | 1,713,670,000 | 1,630,234,000 | ||||||||||||||||
property, plant and equipment | 2,095,000,000 | 2,074,000,000 | 2,026,000,000 | 1,994,000,000 | 1,882,000,000 | 1,780,000,000 | 1,789,000,000 | 1,738,000,000 | 1,713,000,000 | 1,707,000,000 | 1,584,000,000 | 1,599,000,000 | 1,596,000,000 | 1,600,000,000 | 1,507,000,000 | 1,545,000,000 | 1,579,000,000 | 1,598,000,000 | 1,584,000,000 | 1,590,000,000 | 1,556,000,000 | 1,567,000,000 | 1,550,000,000 | 1,496,000,000 | 1,450,000,000 | 1,466,000,000 | 1,390,000,000 | 1,372,000,000 | 1,341,000,000 | 1,353,000,000 | 1,341,000,000 | 1,355,000,000 | 1,411,000,000 | 1,403,000,000 | 1,398,000,000 | 1,373,000,000 | 1,328,000,000 | 1,312,000,000 | 1,472,100,000 | 1,465,500,000 | 1,351,400,000 | 1,359,900,000 | 1,234,236,000 | 1,221,606,000 | 440,998,000 | 452,969,000 | 462,724,000 | 450,327,000 | 409,399,000 | 138,112,000 | 133,411,000 | 148,269,000 | 167,507,000 | 182,298,000 | 233,799,000 | 233,799,000 | 238,457,000 | 238,457,000 | 235,233,000 | 235,233,000 | 223,114,000 | 212,988,000 | 212,988,000 | ||
intangible assets | 4,404,000,000 | 4,643,000,000 | 4,830,000,000 | 5,047,000,000 | 5,297,000,000 | 5,551,000,000 | 5,652,000,000 | 5,903,000,000 | 6,183,000,000 | 6,456,000,000 | 6,728,000,000 | 5,299,000,000 | 5,552,000,000 | 5,800,000,000 | 6,024,000,000 | 6,322,000,000 | 6,632,000,000 | 6,948,000,000 | 7,258,000,000 | 7,624,000,000 | 7,997,000,000 | 8,445,000,000 | 8,923,000,000 | 9,297,000,000 | 9,726,000,000 | 10,201,000,000 | 10,650,000,000 | 11,196,000,000 | 11,683,000,000 | 12,001,000,000 | 12,655,000,000 | 13,393,000,000 | 14,464,000,000 | 15,211,000,000 | 16,023,000,000 | 17,516,000,000 | 18,186,000,000 | 18,884,000,000 | 21,335,800,000 | 22,346,000,000 | 22,382,100,000 | 23,149,700,000 | 12,848,160,000 | 13,090,339,000 | 9,289,669,000 | 9,227,321,000 | 9,308,669,000 | 8,035,717,000 | 8,121,556,000 | 1,379,768,000 | 1,414,853,000 | 720,372,000 | 745,822,000 | 602,542,000 | 616,526,000 | 616,526,000 | 630,514,000 | 630,514,000 | 654,822,000 | 654,822,000 | 669,095,000 | 683,372,000 | 683,372,000 | ||
goodwill | 9,807,000,000 | 11,271,000,000 | 11,287,000,000 | 11,298,000,000 | 11,153,000,000 | 11,087,000,000 | 11,171,000,000 | 11,127,000,000 | 11,160,000,000 | 11,183,000,000 | 11,187,000,000 | 11,628,000,000 | 11,579,000,000 | 11,547,000,000 | 12,044,000,000 | 12,266,000,000 | 12,427,000,000 | 12,457,000,000 | 12,477,000,000 | 12,527,000,000 | 12,485,000,000 | 13,044,000,000 | 13,160,000,000 | 13,084,000,000 | 13,034,000,000 | 13,126,000,000 | 13,052,000,000 | 13,160,000,000 | 13,121,000,000 | 13,142,000,000 | 13,290,000,000 | 13,283,000,000 | 13,432,000,000 | 15,593,000,000 | 15,573,000,000 | 15,892,000,000 | 15,753,000,000 | 15,794,000,000 | 18,511,800,000 | 18,600,700,000 | 17,374,700,000 | 17,233,100,000 | 9,752,100,000 | 9,742,003,000 | 5,277,798,000 | 5,165,247,000 | 5,141,366,000 | 3,799,613,000 | 3,724,341,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | 100,294,000 | ||
deferred tax assets | 1,845,000,000 | 1,843,000,000 | 2,050,000,000 | 2,025,000,000 | 1,977,000,000 | 1,968,000,000 | 2,188,000,000 | 2,187,000,000 | 2,149,000,000 | 2,101,000,000 | 2,189,000,000 | 2,191,000,000 | 2,163,000,000 | 2,166,000,000 | 2,372,000,000 | 2,283,000,000 | 2,282,000,000 | 2,252,000,000 | 2,266,000,000 | 2,255,000,000 | 2,150,000,000 | 2,137,000,000 | 1,913,000,000 | 1,874,000,000 | 1,740,000,000 | 1,690,000,000 | 1,868,000,000 | 1,799,000,000 | 1,754,000,000 | 1,676,000,000 | 1,641,000,000 | 1,654,000,000 | 1,660,000,000 | 433,000,000 | 166,000,000 | 140,000,000 | 142,000,000 | 146,000,000 | 304,700,000 | 163,200,000 | 727,200,000 | 711,400,000 | 366,914,000 | 221,934,000 | 198,674,000 | 198,879,000 | 195,007,000 | 150,539,000 | 150,362,000 | ||||||||||||||||
other non-current assets | 369,000,000 | 378,000,000 | 382,000,000 | 388,000,000 | 380,000,000 | 363,000,000 | 389,000,000 | 329,000,000 | 312,000,000 | 307,000,000 | 328,000,000 | 325,000,000 | 318,000,000 | 326,000,000 | 341,000,000 | 338,000,000 | 334,000,000 | 340,000,000 | 343,000,000 | 596,000,000 | 617,000,000 | 664,000,000 | 345,000,000 | 367,000,000 | 411,000,000 | 411,000,000 | 402,000,000 | 360,000,000 | 377,000,000 | 109,000,000 | 108,000,000 | 124,000,000 | 107,000,000 | 99,000,000 | 152,000,000 | 111,000,000 | 190,000,000 | 184,000,000 | |||||||||||||||||||||||||||
total assets | 24,498,000,000 | 26,366,000,000 | 26,824,000,000 | 27,266,000,000 | 26,421,000,000 | 26,523,000,000 | 26,540,000,000 | 26,495,000,000 | 26,913,000,000 | 27,350,000,000 | 27,064,000,000 | 25,503,000,000 | 25,445,000,000 | 25,686,000,000 | 26,298,000,000 | 28,171,000,000 | 29,090,000,000 | 29,202,000,000 | 29,252,000,000 | 30,042,000,000 | 30,197,000,000 | 31,199,000,000 | 31,562,000,000 | 31,396,000,000 | 31,865,000,000 | 33,863,000,000 | 31,667,000,000 | 32,354,000,000 | 32,551,000,000 | 32,492,000,000 | 33,777,000,000 | 34,448,000,000 | 35,798,000,000 | 37,497,000,000 | 39,974,000,000 | 41,733,000,000 | 42,333,000,000 | 43,529,000,000 | 47,662,200,000 | 49,019,900,000 | 48,454,600,000 | 48,343,200,000 | 27,970,797,000 | 28,204,384,000 | 19,782,258,000 | 17,486,467,000 | 17,950,379,000 | 14,146,208,000 | 14,019,820,000 | ||||||||||||||||
liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 593,000,000 | 600,000,000 | 616,000,000 | 627,000,000 | 620,000,000 | 656,000,000 | 667,000,000 | 579,000,000 | 642,000,000 | 719,000,000 | 569,000,000 | 515,000,000 | 561,000,000 | 521,000,000 | 486,000,000 | 536,000,000 | 471,000,000 | 407,000,000 | 455,000,000 | 442,000,000 | 342,000,000 | 337,000,000 | 379,000,000 | 447,000,000 | 444,000,000 | 503,000,000 | 437,000,000 | 527,000,000 | 429,000,000 | 411,000,000 | 440,000,000 | 417,000,000 | 428,000,000 | 365,000,000 | 407,000,000 | 371,000,000 | 368,000,000 | 324,000,000 | 425,900,000 | 438,100,000 | 476,800,000 | 415,800,000 | 326,970,000 | 412,943,000 | 284,544,000 | 183,021,000 | 227,384,000 | 166,688,000 | 156,178,000 | ||||||||||||||||
accrued and other current liabilities | 3,037,000,000 | 3,344,000,000 | 3,598,000,000 | 3,469,000,000 | 3,354,000,000 | 3,422,000,000 | 3,386,000,000 | 3,338,000,000 | 3,225,000,000 | 3,133,000,000 | 3,119,000,000 | 3,008,000,000 | 2,916,000,000 | 2,988,000,000 | 2,934,000,000 | 4,311,000,000 | 4,303,000,000 | 4,791,000,000 | 4,982,000,000 | 5,075,000,000 | 4,556,000,000 | 4,576,000,000 | 4,353,000,000 | 4,270,000,000 | 4,438,000,000 | 4,511,000,000 | 3,198,000,000 | 3,122,000,000 | 3,255,000,000 | 3,197,000,000 | 3,424,000,000 | 3,427,000,000 | 3,560,000,000 | 3,694,000,000 | 3,396,000,000 | 3,259,000,000 | 3,484,000,000 | 3,175,000,000 | 3,335,500,000 | 3,337,900,000 | 3,293,500,000 | 3,054,700,000 | 1,800,193,000 | ||||||||||||||||||||||
financial leases | 11,000,000 | 11,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current portion of long-term debt | 889,000,000 | 225,000,000 | 579,000,000 | 879,000,000 | 282,000,000 | 2,674,000,000 | 453,000,000 | 452,000,000 | 538,000,000 | 450,000,000 | 536,000,000 | 444,000,000 | 446,000,000 | 432,000,000 | 411,000,000 | 150,000,000 | 346,000,000 | 1,000,000 | 294,100,000 | 675,100,000 | 707,000,000 | 590,900,000 | 204,756,000 | 360,964,000 | 346,875,000 | 289,676,000 | 480,182,000 | 207,688,000 | 195,154,000 | ||||||||||||||||||||||||||||||||||||
total current liabilities | 4,530,000,000 | 4,180,000,000 | 4,793,000,000 | 4,975,000,000 | 4,256,000,000 | 6,752,000,000 | 4,506,000,000 | 4,369,000,000 | 4,405,000,000 | 4,302,000,000 | 4,224,000,000 | 3,967,000,000 | 3,923,000,000 | 3,941,000,000 | 3,831,000,000 | 4,997,000,000 | 4,774,000,000 | 5,198,000,000 | 5,437,000,000 | 5,517,000,000 | 4,898,000,000 | 4,913,000,000 | 4,732,000,000 | 4,718,000,000 | 4,886,000,000 | 6,248,000,000 | 3,735,000,000 | 3,705,000,000 | 3,941,000,000 | 3,836,000,000 | 4,162,000,000 | 4,074,000,000 | 3,990,000,000 | 4,268,000,000 | 4,728,000,000 | 4,465,000,000 | 4,247,000,000 | 3,609,000,000 | 4,226,400,000 | 4,597,400,000 | 4,650,500,000 | 4,291,000,000 | 2,512,396,000 | 2,853,082,000 | 1,761,818,000 | 1,646,128,000 | 1,822,752,000 | 1,158,508,000 | 1,049,197,000 | ||||||||||||||||
acquisition-related contingent consideration | 213,000,000 | 254,000,000 | 224,000,000 | 264,000,000 | 282,000,000 | 310,000,000 | 248,000,000 | 230,000,000 | 225,000,000 | 253,000,000 | 247,000,000 | 197,000,000 | 219,000,000 | 208,000,000 | 189,000,000 | 188,000,000 | 193,000,000 | 202,000,000 | 207,000,000 | 206,000,000 | 202,000,000 | 216,000,000 | 275,000,000 | 279,000,000 | 268,000,000 | 262,000,000 | 267,000,000 | 271,000,000 | 264,000,000 | 298,000,000 | 282,000,000 | 310,000,000 | 320,000,000 | 344,000,000 | 345,000,000 | 755,000,000 | 818,000,000 | 52,000,000 | 170,900,000 | 146,300,000 | 161,600,000 | 191,400,000 | 114,460,000 | 125,524,000 | 91,029,000 | 97,517,000 | 102,559,000 | 112,274,000 | 67,115,000 | ||||||||||||||||
non-current portion of financial leases | 20,000,000 | 23,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-current portion of long-term debt | 19,875,000,000 | 20,592,000,000 | 20,463,000,000 | 20,859,000,000 | 21,228,000,000 | 18,942,000,000 | 21,054,000,000 | 21,208,000,000 | 21,536,000,000 | 21,938,000,000 | 21,894,000,000 | 20,108,000,000 | 20,207,000,000 | 20,334,000,000 | 20,804,000,000 | 21,664,000,000 | 23,168,000,000 | 22,654,000,000 | 22,358,000,000 | 23,439,000,000 | 23,738,000,000 | 23,925,000,000 | 24,343,000,000 | 24,357,000,000 | 24,424,000,000 | 24,661,000,000 | 23,466,000,000 | 24,023,000,000 | 23,924,000,000 | 24,077,000,000 | 24,433,000,000 | 24,858,000,000 | 25,266,000,000 | 25,235,000,000 | 26,216,000,000 | 27,648,000,000 | 28,198,000,000 | 29,845,000,000 | |||||||||||||||||||||||||||
deferred tax liabilities | 179,000,000 | 147,000,000 | 145,000,000 | 144,000,000 | 134,000,000 | 128,000,000 | 169,000,000 | 170,000,000 | 170,000,000 | 163,000,000 | 213,000,000 | 215,000,000 | 205,000,000 | 202,000,000 | 422,000,000 | 545,000,000 | 552,000,000 | 529,000,000 | 513,000,000 | 516,000,000 | 520,000,000 | 528,000,000 | 650,000,000 | 694,000,000 | 690,000,000 | 705,000,000 | 879,000,000 | 884,000,000 | 880,000,000 | 885,000,000 | 1,131,000,000 | 1,130,000,000 | 1,139,000,000 | 1,180,000,000 | 2,237,000,000 | 4,273,000,000 | 4,490,000,000 | 5,434,000,000 | 5,879,200,000 | 5,896,600,000 | 11,600,000 | 38,200,000 | 66,017,000 | 64,191,000 | 4,363,000 | 4,291,000 | 4,403,000 | 8,786,000 | 7,525,000 | ||||||||||||||||
other non-current liabilities | 763,000,000 | 793,000,000 | 843,000,000 | 877,000,000 | 761,000,000 | 713,000,000 | 805,000,000 | 745,000,000 | 751,000,000 | 776,000,000 | 721,000,000 | 745,000,000 | 746,000,000 | 741,000,000 | 619,000,000 | 524,000,000 | 544,000,000 | 653,000,000 | 872,000,000 | 975,000,000 | 963,000,000 | 1,012,000,000 | 907,000,000 | 802,000,000 | 807,000,000 | 851,000,000 | 760,000,000 | 783,000,000 | 763,000,000 | 581,000,000 | 532,000,000 | 518,000,000 | 560,000,000 | 526,000,000 | 102,000,000 | 104,000,000 | 88,000,000 | 107,000,000 | |||||||||||||||||||||||||||
total liabilities | 25,580,000,000 | 25,989,000,000 | 26,468,000,000 | 27,119,000,000 | 26,661,000,000 | 26,845,000,000 | 26,782,000,000 | 26,722,000,000 | 27,087,000,000 | 27,432,000,000 | 27,299,000,000 | 25,232,000,000 | 25,300,000,000 | 25,426,000,000 | 25,865,000,000 | 27,918,000,000 | 29,231,000,000 | 29,236,000,000 | 29,387,000,000 | 30,653,000,000 | 30,321,000,000 | 30,594,000,000 | 30,907,000,000 | 30,850,000,000 | 31,075,000,000 | 32,727,000,000 | 29,107,000,000 | 29,666,000,000 | 29,772,000,000 | 29,677,000,000 | 30,540,000,000 | 30,890,000,000 | 31,275,000,000 | 31,553,000,000 | 34,552,000,000 | 37,704,000,000 | 38,339,000,000 | 40,271,000,000 | 42,259,100,000 | 43,244,300,000 | 41,989,900,000 | 41,784,800,000 | 22,737,475,000 | 23,143,194,000 | 14,079,729,000 | 13,899,479,000 | 14,232,981,000 | 10,361,026,000 | 10,324,389,000 | ||||||||||||||||
commitments and contingencies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(deficit) equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 373,464,760 and 370,531,987 issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 10,542,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
additional paid-in capital | 295,000,000 | 357,000,000 | 275,000,000 | 250,000,000 | 220,000,000 | 234,000,000 | 201,000,000 | 181,000,000 | 164,000,000 | 214,000,000 | 190,000,000 | 188,000,000 | 171,000,000 | 159,000,000 | 129,000,000 | 104,000,000 | 415,000,000 | 462,000,000 | 437,000,000 | 413,000,000 | 393,000,000 | 454,000,000 | 435,000,000 | 411,000,000 | 396,000,000 | 429,000,000 | 406,000,000 | 384,000,000 | 374,000,000 | 413,000,000 | 409,000,000 | 391,000,000 | 382,000,000 | 380,000,000 | 368,000,000 | 350,000,000 | 374,000,000 | 351,000,000 | 380,400,000 | 351,600,000 | 244,600,000 | 234,000,000 | 228,853,000 | 251,654,000 | 225,289,000 | 264,982,000 | 267,118,000 | 270,183,000 | 283,061,000 | ||||||||||||||||
accumulated deficit | -11,090,000,000 | -9,667,000,000 | -9,555,000,000 | -9,734,000,000 | -9,882,000,000 | -9,824,000,000 | -9,917,000,000 | -9,832,000,000 | -9,842,000,000 | -9,778,000,000 | -9,739,000,000 | -9,361,000,000 | -9,387,000,000 | -9,186,000,000 | -8,776,000,000 | -9,175,000,000 | -9,030,000,000 | -8,961,000,000 | -9,030,000,000 | -9,218,000,000 | -8,623,000,000 | -8,013,000,000 | -7,860,000,000 | -7,931,000,000 | -7,605,000,000 | -7,452,000,000 | -5,936,000,000 | -5,887,000,000 | -5,716,000,000 | -5,664,000,000 | -5,320,000,000 | -4,970,000,000 | -4,209,000,000 | -2,725,000,000 | -3,239,000,000 | -4,539,000,000 | -4,502,000,000 | -5,129,000,000 | -3,425,700,000 | -3,123,400,000 | -2,338,500,000 | -2,387,900,000 | -3,278,529,000 | -3,402,294,000 | -2,429,051,000 | -2,423,731,000 | -2,370,976,000 | -2,281,834,000 | -2,245,886,000 | ||||||||||||||||
accumulated other comprehensive loss | -1,806,000,000 | -1,760,000,000 | -1,800,000,000 | -1,790,000,000 | -2,029,000,000 | -2,179,000,000 | -1,947,000,000 | -2,007,000,000 | -1,917,000,000 | -1,881,000,000 | -2,051,000,000 | -1,902,000,000 | -1,989,000,000 | -2,056,000,000 | -2,265,000,000 | -2,002,000,000 | -1,974,000,000 | -1,924,000,000 | -1,923,000,000 | -2,182,000,000 | -2,256,000,000 | -2,133,000,000 | -2,207,000,000 | -2,223,000,000 | -2,281,000,000 | -2,086,000,000 | -2,156,000,000 | -2,061,000,000 | -2,116,000,000 | -2,137,000,000 | -2,053,000,000 | -2,068,000,000 | -1,852,000,000 | -1,896,000,000 | -1,888,000,000 | -1,965,000,000 | -2,020,000,000 | -2,108,000,000 | -1,573,700,000 | -1,478,600,000 | -1,463,400,000 | -1,291,500,000 | -132,780,000 | -160,257,000 | -343,901,000 | -196,799,000 | -119,396,000 | -119,838,000 | -226,969,000 | ||||||||||||||||
total bausch health companies inc. shareholders’ deficit | -2,059,000,000 | -554,000,000 | -565,000,000 | -764,000,000 | -1,183,000,000 | -1,279,000,000 | -1,174,000,000 | -1,175,000,000 | -1,115,000,000 | -1,022,000,000 | -1,180,000,000 | -663,000,000 | -800,000,000 | -692,000,000 | -525,000,000 | -693,000,000 | -216,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
noncontrolling interest | 977,000,000 | 931,000,000 | 921,000,000 | 911,000,000 | 943,000,000 | 957,000,000 | 932,000,000 | 948,000,000 | 941,000,000 | 940,000,000 | 945,000,000 | 934,000,000 | 945,000,000 | 952,000,000 | 958,000,000 | 946,000,000 | 75,000,000 | 72,000,000 | 69,000,000 | 76,000,000 | 73,000,000 | 70,000,000 | 68,000,000 | 72,000,000 | 71,000,000 | 73,000,000 | 78,000,000 | 87,000,000 | 86,000,000 | 82,000,000 | 84,000,000 | 91,000,000 | 99,000,000 | 95,000,000 | 95,000,000 | 98,000,000 | 101,000,000 | 106,000,000 | 107,200,000 | 120,100,000 | 122,400,000 | 123,000,000 | 114,599,000 | 112,077,000 | |||||||||||||||||||||
total (deficit) equity | -1,082,000,000 | -82,000,000 | -235,000,000 | -34,000,000 | -135,000,000 | -611,000,000 | -124,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and equity | 24,498,000,000 | 26,366,000,000 | 26,824,000,000 | 27,266,000,000 | 25,503,000,000 | 25,445,000,000 | 25,686,000,000 | 26,298,000,000 | 28,171,000,000 | 31,199,000,000 | 31,562,000,000 | 31,396,000,000 | 31,865,000,000 | 33,863,000,000 | 31,667,000,000 | 32,354,000,000 | 32,551,000,000 | 32,492,000,000 | 33,777,000,000 | 34,448,000,000 | 35,798,000,000 | 37,497,000,000 | 39,974,000,000 | 41,733,000,000 | 42,333,000,000 | 43,529,000,000 | 47,662,200,000 | 49,019,900,000 | 48,454,600,000 | 48,343,200,000 | 27,970,797,000 | 28,204,384,000 | |||||||||||||||||||||||||||||||||
equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 370,531,987 and 367,843,058 issued and outstanding at december 31, 2025 and 2024, respectively | 10,516,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total equity | 377,000,000 | 356,000,000 | 147,000,000 | 271,000,000 | 145,000,000 | 260,000,000 | 433,000,000 | 253,000,000 | 605,000,000 | 655,000,000 | 546,000,000 | 790,000,000 | 1,136,000,000 | 2,560,000,000 | 2,688,000,000 | 2,779,000,000 | 2,815,000,000 | 3,237,000,000 | 3,558,000,000 | 4,523,000,000 | 5,944,000,000 | 5,422,000,000 | 4,029,000,000 | 3,994,000,000 | 3,258,000,000 | 5,403,100,000 | 5,775,600,000 | 6,464,700,000 | 6,558,400,000 | 5,233,322,000 | 5,061,190,000 | ||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 370,473,221 and 367,843,058 issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 10,515,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 369,749,489 and 367,843,058 issued and outstanding at june 30, 2025 and december 31, 2024, respectively | 10,510,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deficit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 369,539,455 and 367,843,058 issued and outstanding at march 31, 2025 and december 31, 2024, respectively | 10,508,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total deficit | -240,000,000 | -322,000,000 | -242,000,000 | -227,000,000 | -174,000,000 | -141,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and deficit | 26,421,000,000 | 26,523,000,000 | 26,540,000,000 | 26,495,000,000 | 26,913,000,000 | 29,090,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 367,843,058 and 365,238,917 issued and outstanding at december 31, 2024 and 2023, respectively | 10,490,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 367,695,267 and 365,238,917 issued and outstanding at september 30, 2024 and december 31, 2023, respectively | 10,489,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 366,985,967 and 365,238,917 issued and outstanding at june 30, 2024 and december 31, 2023, respectively | 10,483,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 366,674,264 and 365,238,917 issued and outstanding at march 31, 2024 and december 31, 2023, respectively | 10,480,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash and other settlement deposits | 15,000,000 | 27,000,000 | 11,000,000 | 1,220,000,000 | 1,211,000,000 | 1,537,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 365,238,917 and 361,898,846 issued and outstanding at december 31, 2023 and 2022, respectively | 10,423,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and (deficit) equity | 27,350,000,000 | 27,064,000,000 | 29,202,000,000 | 29,252,000,000 | 30,042,000,000 | 30,197,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 365,043,317 and 361,898,846 issued and outstanding at september 30, 2023 and december 31, 2022, respectively | 10,420,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 364,063,514 and 361,898,846 issued and outstanding at june 30, 2023 and december 31, 2022, respectively | 10,412,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 363,607,062 and 361,898,846 issued and outstanding at march 31, 2023 and december 31, 2022, respectively | 10,405,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 361,898,846 and 359,405,748 issued and outstanding at december 31, 2022 and 2021, respectively | 10,391,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 361,781,292 and 359,405,748 issued and outstanding at september 30, 2022 and december 31, 2021, respectively | 10,387,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 361,571,921 and 359,405,748 issued and outstanding at june 30, 2022 and december 31, 2021, respectively | 10,380,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 361,331,665 and 359,405,748 issued and outstanding at march 31, 2022 and december 31, 2021, respectively | 10,373,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 359,405,748 and 355,422,347 issued and outstanding at december 31, 2021 and 2020, respectively | 10,317,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total bausch health companies inc. shareholders’ (deficit) equity | -106,000,000 | -204,000,000 | -687,000,000 | -197,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
/s/ joseph c. papa | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
joseph c. papa | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
chief executive officer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 359,154,635 and 355,422,347 issued and outstanding at september 30, 2021 and december 31, 2020, respectively | 10,312,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
revenues | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
product sales | 2,088,000,000 | 2,076,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other revenues | 23,000,000 | 24,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of goods sold | 574,000,000 | 604,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of other revenues | 8,000,000 | 8,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
selling, general and administrative | 653,000,000 | 685,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
research and development | 121,000,000 | 115,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of intangible assets | 338,000,000 | 360,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill impairments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
asset impairments, including loss on assets held for sale | 18,000,000 | 47,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restructuring, integration, separation and ipo costs | 8,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other income | -183,000,000 | 542,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating income | 574,000,000 | -270,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest income | 2,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest expense | -351,000,000 | -364,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on extinguishment of debt | -12,000,000 | -45,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange and other | 3,000,000 | 7,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before benefit from income taxes | 216,000,000 | -670,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(benefit from) benefit from income taxes | -25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income | 191,000,000 | -593,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net (income) loss attributable to noncontrolling interest | -3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to bausch health companies inc. | 188,000,000 | -595,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share attributable to bausch health companies inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 520,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 520,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average common shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 358,653,899 and 355,422,347 issued and outstanding at june 30, 2021 and december 31, 2020, respectively | 10,300,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restructuring, integration and separation costs | 9,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
benefit from income taxes | 77,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to noncontrolling interest | -2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted loss per share attributable to bausch health companies inc. | -1,660,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted weighted-average common shares | 359,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 358,104,438 and 355,422,347 issued and outstanding at march 31, 2021 and december 31, 2020, respectively | 10,289,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current portion of long-term debt and other | 1,000,000 | 4,000,000 | 1,234,000,000 | 100,000,000 | 56,000,000 | 257,000,000 | 228,000,000 | 298,000,000 | 230,000,000 | 2,000,000 | 209,000,000 | 925,000,000 | 813,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 355,422,347 and 352,562,636 issued and outstanding at december 31, 2020 and 2019, respectively | 10,227,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total bausch health companies inc. shareholders’ equity | 535,000,000 | 587,000,000 | 474,000,000 | 719,000,000 | 1,063,000,000 | 2,482,000,000 | 2,601,000,000 | 2,693,000,000 | 2,733,000,000 | 3,153,000,000 | 3,467,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 355,026,950 and 352,562,636 issued and outstanding at september 30, 2020 and december 31, 2019, respectively | 10,219,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 354,927,516 and 352,562,636 issued and outstanding at june 30, 2020 and december 31, 2019, respectively | 10,217,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 354,579,990 and 352,562,636 issued and outstanding at march 31, 2020 and december 31, 2019, respectively | 10,209,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 352,562,636 and 349,871,102 issued and outstanding at december 31, 2019 and 2018, respectively | 10,172,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 352,387,430 and 349,871,102 issued and outstanding at september 30, 2019 and december 31, 2018, respectively | 10,168,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 352,248,896 and 349,871,102 issued and outstanding at june 30, 2019 and december 31, 2018, respectively | 10,165,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 351,873,984 and 349,871,102 issued and outstanding at march 31, 2019 and december 31, 2018, respectively | 10,151,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 349,871,102 and 348,708,567 issued and outstanding at december 31, 2018 and 2017, respectively | 10,121,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 349,754,139 and 348,708,567 issued and outstanding at september 30, 2018 and december 31, 2017, respectively | 10,117,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 349,600,960 and 348,708,567 issued and outstanding at june 30, 2018 and december 31, 2017, respectively | 10,114,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 349,219,074 and 348,708,567 issued and outstanding at march 31, 2018 and december 31, 2017, respectively | 10,103,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total valeant pharmaceuticals international, inc. shareholders’ equity | 4,424,000,000 | 5,849,000,000 | 5,327,000,000 | 3,931,000,000 | 3,893,000,000 | 3,152,000,000 | 5,295,900,000 | 5,655,500,000 | 6,342,300,000 | 6,435,400,000 | 5,118,723,000 | 4,949,113,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets held for sale | 16,000,000 | 77,000,000 | 240,000,000 | 261,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-current assets held for sale | 12,000,000 | 718,000,000 | 709,000,000 | 1,401,000,000 | 2,132,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities held for sale | 22,000,000 | 49,000,000 | 57,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-current liabilities held for sale | 461,000,000 | 48,000,000 | 57,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 348,708,567 and 347,821,606 issued and outstanding at december 31, 2017 and 2016, respectively | 10,090,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
pension and other benefit liabilities | 198,000,000 | 201,000,000 | 197,000,000 | 195,000,000 | 191,600,000 | 194,800,000 | 221,900,000 | 226,400,000 | 172,016,000 | 230,978,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities for uncertain tax positions | 265,000,000 | 258,000,000 | 253,000,000 | 184,000,000 | 116,300,000 | 117,700,000 | 109,300,000 | 101,200,000 | 169,117,000 | 159,673,000 | 105,766,000 | 107,020,000 | 103,658,000 | 99,544,000 | 95,945,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 348,582,556 and 347,821,606 issued and outstanding at september 30, 2017 and december 31, 2016, respectively | 10,086,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 348,516,280 and 347,821,606 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued and outstanding at june 30, 2017 and december 31, 2016, respectively | 10,085,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 347,860,891 and 347,821,606 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued and outstanding at march 31, 2017 and december 31, 2016, respectively | 10,041,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 347,821,606 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
342,926,531 issued and outstanding at december 31, 2016 and 2015, respectively | 10,038,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term assets | 219,400,000 | 210,800,000 | 236,100,000 | 167,000,000 | 195,470,000 | 241,952,000 | 199,436,000 | 180,410,000 | 176,580,000 | 97,469,000 | 89,511,000 | 34,216,000 | 39,510,000 | 25,448,000 | 29,734,000 | 34,541,000 | 38,506,000 | 38,506,000 | 35,882,000 | 35,882,000 | 50,310,000 | 50,310,000 | 54,648,000 | 59,124,000 | 59,124,000 | ||||||||||||||||||||||||||||||||||||||||
long-term debt | 30,773,200,000 | 31,303,400,000 | 30,176,300,000 | 30,290,200,000 | 17,162,946,000 | 17,043,750,000 | 10,447,230,000 | 10,327,444,000 | 10,535,443,000 | 7,422,558,000 | 7,356,021,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term liabilities | 168,700,000 | 182,700,000 | 209,100,000 | 208,800,000 | 160,493,000 | 163,979,000 | 161,711,000 | 167,079,000 | 134,166,000 | 123,502,000 | 123,024,000 | 116,718,000 | 116,718,000 | 104,026,000 | 104,026,000 | 104,611,000 | 107,953,000 | 107,953,000 | |||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 343,030,673 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
342,926,531 issued and outstanding at june 30, 2016 and december 31, 2015, respectively | 9,914,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 343,019,163 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
342,926,531 issued and outstanding at march 31, 2016 and december 31, 2015, respectively | 9,905,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 343,094,009 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
334,402,964 issued and outstanding at september 30, 2015 and december 31, 2014, respectively | 9,899,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 342,769,031 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
334,402,964 issued and outstanding at june 30, 2015 and december 31, 2014, respectively | 9,880,800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | 1,814,769,000 | 1,643,148,000 | 1,127,006,000 | 1,054,161,000 | 913,835,000 | 805,010,000 | 611,204,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
assets held for sale | 15,942,000 | 53,457,000 | 54,400,000 | 56,930,000 | 90,983,000 | 9,925,000 | 28,203,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 333,036,637 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
303,861,272 issued and outstanding at december 31, 2013 and 2012, respectively | 8,301,179,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued liabilities and other current liabilities | 1,889,460,000 | 1,035,007,000 | 1,071,623,000 | 981,282,000 | 634,722,000 | 600,657,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 332,757,906 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
303,861,272 issued and outstanding at september 30, 2013 and december 31, 2012, respectively | 8,260,010,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders’ equity | 1,291,248,000 | 1,254,132,000 | 1,163,886,000 | 1,183,155,000 | 1,290,624,000 | 1,290,624,000 | 1,297,819,000 | 1,297,819,000 | 1,379,250,000 | 1,379,250,000 | 1,377,849,000 | 1,284,927,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 332,455,182 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
303,861,272 issued and outstanding at june 30, 2013 and december 31, 2012, respectively | 8,250,192,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders’ equity | 5,702,529,000 | 3,586,988,000 | 3,717,398,000 | 3,785,182,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and shareholders’ equity | 19,782,258,000 | 17,486,467,000 | 17,950,379,000 | 14,146,208,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 303,801,803 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
303,861,272 issued and outstanding at march 31, 2013 and december 31, 2012, respectively | 5,942,536,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
marketable securities | 4,410,000 | 14,855,000 | 14,938,000 | 21,916,000 | 23,141,000 | 23,065,000 | 23,758,000 | 23,758,000 | 24,417,000 | 24,417,000 | 29,143,000 | 29,143,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes payable | 19,910,000 | 10,208,000 | 15,537,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred revenue | 7,032,000 | 18,142,000 | 7,031,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 303,861,272 and 306,371,032 issued and outstanding at december 31, 2012 and 2011, respectively | 5,940,652,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 302,899,442 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
306,371,032 issued and outstanding at september 30, 2012 and december 31, 2011, respectively | 5,916,671,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders' equity | 1,201,599,000 | 1,342,468,000 | 1,342,468,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares, no par value, unlimited shares authorized, 302,052,589 and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
306,371,032 issued and outstanding at june 30, 2012 and december 31, 2011, respectively | 5,885,225,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders' equity | 3,695,431,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and shareholders' equity | 14,019,820,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other current assets | 195,598,000 | 187,871,000 | 172,817,000 | 197,066,000 | 310,000,000 | 223,954,000 | 223,954,000 | 273,376,000 | 273,376,000 | 203,106,000 | 203,106,000 | 203,493,000 | 212,792,000 | 212,792,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
long-term investment | 725,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred tax assets, net of valuation allowance | 104,800,000 | 116,800,000 | 18,200,000 | 18,200,000 | 18,000,000 | 18,000,000 | 20,700,000 | 20,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders’ equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities | 219,387,000 | 217,009,000 | 267,166,000 | 188,290,000 | 350,975,000 | 390,225,000 | 390,225,000 | 367,578,000 | 367,578,000 | 228,438,000 | 228,438,000 | 275,705,000 | 742,214,000 | 742,214,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
long-term liabilities | 511,664,000 | 587,229,000 | 154,800,000 | 148,785,000 | 105,475,000 | 108,887,000 | 108,887,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
defend tax assets, net of valuation allowance | 108,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term investments | 102,000 | 192,000 | 14,609,000 | 23,637,000 | 23,637,000 | 24,834,000 | 24,834,000 | 26,900,000 | 26,900,000 | 38,063,000 | 55,227,000 | 55,227,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders' equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term investments | 79,725,000 | 79,725,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term obligations | 66 | 1,337,000 | 1,337,000 | 411,791,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total assets under u.s. gaap | 2,192,442 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
canadian gaap adjustments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
marketable securities/long-term investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net unrealized holding gain on available-for-sale investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired research and development,,, | 112,299 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
value of consideration paid on acquisition of fuisz technologies ltd. | 7,763 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
settlement of fuisz pre-acquisition contract | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other | 2,312 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total assets under canadian gaap | 2,299,749 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities under u.s. gaap | 890,185 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities under canadian gaap | 890,251 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders’ equity under u.s. gaap | 1,302,257 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation | 43,547 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accretion of convertible debt | 26,116 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
value of consideration paid on acquisition of fuisz | 7,763 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired research and development | 112,299 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cumulative translation adjustment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders’ equity under canadian gaap | 1,409,498 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and shareholders’ equity under canadian gaap | 2,299,749 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
working capital | 647,337,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-lived assets | 1,055,369,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-06-30 | 2016-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2009-09-30 | 2008-12-31 | 2008-11-06 | 2008-08-13 | 2008-05-08 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-05-18 | 2007-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss | -1,431,000,000 | -86,000,000 | 98,000,000 | -92,000,000 | -1,000,000 | -77,000,000 | 27,000,000 | -209,000,000 | -139,000,000 | -66,000,000 | 72,000,000 | 191,000,000 | -593,000,000 | -607,000,000 | -152,000,000 | 70,000,000 | -325,000,000 | -152,000,000 | -48,000,000 | -170,000,000 | -48,000,000 | -27,530,000 | |||||||||||||||||||||||||||||||||
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization of intangible assets | 295,000,000 | 290,000,000 | 306,000,000 | 307,000,000 | 305,000,000 | 307,000,000 | 322,000,000 | 318,000,000 | 320,000,000 | 329,000,000 | 301,000,000 | 315,000,000 | 319,000,000 | 360,000,000 | 335,000,000 | 347,000,000 | 352,000,000 | 363,000,000 | 382,000,000 | 404,000,000 | 403,000,000 | 428,000,000 | 436,000,000 | 480,000,000 | 481,000,000 | 492,000,000 | 520,000,000 | 531,000,000 | 532,000,000 | 546,000,000 | 703,000,000 | 784,000,000 | 786,000,000 | 819,000,000 | 698,000,000 | 667,000,000 | 674,000,000 | ||||||||||||||||||
amortization and write-off of debt premiums, discounts and issuance costs | 14,000,000 | 16,000,000 | 41,000,000 | 15,000,000 | 13,000,000 | 14,000,000 | 14,000,000 | 28,000,000 | 12,000,000 | 11,000,000 | 22,000,000 | 50,000,000 | 14,000,000 | 17,000,000 | 12,000,000 | 13,000,000 | 13,000,000 | 17,000,000 | 15,000,000 | 17,000,000 | 15,000,000 | 17,000,000 | |||||||||||||||||||||||||||||||||
goodwill impairments | 1,426,000,000 | 119,000,000 | 0 | 0 | 469,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition-related contingent consideration | 12,000,000 | 36,000,000 | -32,000,000 | -29,000,000 | -11,000,000 | -5,000,000 | 25,000,000 | -4,000,000 | -2,000,000 | 19,000,000 | 26,000,000 | -17,000,000 | 31,000,000 | 27,000,000 | 4,000,000 | -5,000,000 | 3,000,000 | 3,000,000 | -9,000,000 | 22,000,000 | 2,000,000 | 11,000,000 | 13,000,000 | 10,000,000 | 3,000,000 | 20,000,000 | -21,000,000 | 14,000,000 | -19,000,000 | -6,000,000 | 2,000,000 | 8,000,000 | -238,000,000 | -49,000,000 | -10,000,000 | 6,900,000 | 2,400,000 | 5,736,000 | -38,664,000 | 5,854,000 | -2,185,000 | -10,896,000 | -2,099,000 | ||||||||||||
allowances for losses on trade receivable and inventories | 26,000,000 | 12,000,000 | 10,000,000 | 26,000,000 | 11,000,000 | 17,000,000 | 15,000,000 | 11,000,000 | 22,000,000 | 10,000,000 | 17,000,000 | 5,000,000 | 14,000,000 | 16,000,000 | 18,000,000 | 17,000,000 | 18,000,000 | 19,000,000 | 15,000,000 | 19,000,000 | 14,000,000 | 13,000,000 | 15,000,000 | 16,000,000 | 17,000,000 | 23,000,000 | 24,000,000 | 24,000,000 | |||||||||||||||||||||||||||
deferred income taxes | 30,000,000 | 155,000,000 | -24,000,000 | -42,000,000 | -9,000,000 | 170,000,000 | -3,000,000 | -44,000,000 | -57,000,000 | 84,000,000 | -3,000,000 | 19,000,000 | -96,000,000 | -16,000,000 | -83,000,000 | -88,000,000 | -17,000,000 | -106,000,000 | -14,000,000 | -262,000,000 | -19,000,000 | -124,000,000 | -70,000,000 | 3,000,000 | -92,000,000 | -25,000,000 | -116,000,000 | -142,000,000 | 40,000,000 | -2,000,000 | -40,000,000 | -1,401,000,000 | -1,778,000,000 | -253,000,000 | -954,000,000 | -330,273,000 | -122,391,000 | -25,865,000 | -37,355,000 | -212,510,000 | -101,243,000 | 3,400,000 | |||||||||||||
net gain on sale of assets | -3,000,000 | 0 | 0 | -4,000,000 | 1,000,000 | -2,000,000 | 0 | 21,000,000 | 0 | -23,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
adjustments to accrued legal settlements | 10,000,000 | 35,000,000 | 8,000,000 | -3,000,000 | 188,000,000 | 21,000,000 | 6,000,000 | 1,000,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
payments of accrued legal settlements | -161,000,000 | -17,000,000 | -92,000,000 | -87,000,000 | -19,000,000 | -8,000,000 | -218,000,000 | -1,000,000 | -3,000,000 | -7,000,000 | -1,000,000 | -1,000,000 | -1,000,000 | 0 | -1,212,000,000 | 0 | -360,000,000 | -207,000,000 | -15,000,000 | -11,000,000 | -118,000,000 | -86,000,000 | -48,000,000 | -31,000,000 | -3,000,000 | -11,000,000 | -3,000,000 | 0 | -1,000,000 | -2,000,000 | -2,000,000 | -50,000,000 | -170,000,000 | 0 | -8,000,000 | -48,600,000 | -2,800,000 | -180,699,000 | 11,578,000 | -8,908,000 | -2,820,000 | -4,061,000 | -35,987,000 | ||||||||||||
share-based compensation | 52,000,000 | 84,000,000 | 43,000,000 | 46,000,000 | 43,000,000 | 43,000,000 | 38,000,000 | 36,000,000 | 33,000,000 | 29,000,000 | 29,000,000 | 33,000,000 | 41,000,000 | 35,000,000 | 33,000,000 | 26,000,000 | 32,000,000 | 33,000,000 | 33,000,000 | 31,000,000 | 31,000,000 | 24,000,000 | 27,000,000 | 27,000,000 | 27,000,000 | 25,000,000 | 26,000,000 | 27,000,000 | 24,000,000 | 22,000,000 | 22,000,000 | 22,000,000 | 21,000,000 | 17,000,000 | 19,000,000 | 23,000,000 | 28,000,000 | 33,700,000 | 63,500,000 | 29,478,000 | 8,619,000 | -1,714,000 | 9,095,000 | 47,689,000 | 3,391,000 | ||||||||||
gain excluded from hedge effectiveness | -3,000,000 | -2,000,000 | -2,000,000 | -3,000,000 | -3,000,000 | -3,000,000 | -4,000,000 | -3,000,000 | -3,000,000 | -3,000,000 | -4,000,000 | -3,000,000 | -3,000,000 | -3,000,000 | -3,000,000 | -6,000,000 | -5,000,000 | -6,000,000 | -6,000,000 | -6,000,000 | |||||||||||||||||||||||||||||||||||
loss on extinguishment of debt | 1,000,000 | -192,000,000 | -570,000,000 | 0 | 12,000,000 | 45,000,000 | 5,000,000 | 8,000,000 | 0 | 27,000,000 | 24,000,000 | 2,000,000 | 0 | 33,000,000 | 7,000,000 | 44,000,000 | 0 | 48,000,000 | 27,000,000 | 57,000,000 | 1,000,000 | 0 | 64,000,000 | 56,853,000 | 21,379,000 | ||||||||||||||||||||||||||||||
payments of contingent consideration adjustments, including accretion | -3,000,000 | -2,000,000 | -2,000,000 | -2,000,000 | -2,000,000 | -3,000,000 | -2,000,000 | -3,000,000 | -2,000,000 | -6,000,000 | -1,000,000 | -1,000,000 | 0 | 0 | -8,000,000 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||
amortization of inventory step-up resulting from acquisitions | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange and other | 5,000,000 | 7,000,000 | 5,000,000 | -21,000,000 | -2,000,000 | 36,000,000 | -15,000,000 | -14,000,000 | -4,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade receivables | 148,000,000 | 65,000,000 | -218,000,000 | -91,000,000 | 110,000,000 | -104,000,000 | 23,000,000 | -72,000,000 | -63,000,000 | -19,000,000 | -231,000,000 | -53,000,000 | 108,000,000 | -31,000,000 | -133,000,000 | -90,000,000 | 197,000,000 | -52,000,000 | -129,000,000 | -108,000,000 | 60,000,000 | 103,000,000 | -356,000,000 | 354,000,000 | 69,000,000 | -71,000,000 | 54,000,000 | -33,000,000 | 89,000,000 | 160,000,000 | -72,000,000 | -76,000,000 | 204,000,000 | 79,000,000 | -114,000,000 | 20,000,000 | 432,000,000 | -48,700,000 | 5,500,000 | ||||||||||||||||
inventories | -14,000,000 | -5,000,000 | 16,000,000 | 7,000,000 | -30,000,000 | -49,000,000 | -42,000,000 | -32,000,000 | -144,000,000 | -100,000,000 | -62,000,000 | -32,000,000 | -128,000,000 | -4,000,000 | -56,000,000 | -65,000,000 | -73,000,000 | 46,000,000 | -15,000,000 | -12,000,000 | -35,000,000 | 101,000,000 | 10,000,000 | -94,000,000 | -94,000,000 | -4,000,000 | -84,000,000 | -53,000,000 | -68,000,000 | 3,000,000 | 4,000,000 | 6,000,000 | -38,000,000 | -59,200,000 | -85,900,000 | -76,551,000 | -12,190,000 | -9,012,000 | -24,948,000 | -70,517,000 | 6,646,000 | ||||||||||||||
prepaid expenses and other current assets | -27,000,000 | 32,000,000 | 5,000,000 | 12,000,000 | -46,000,000 | 13,000,000 | 1,000,000 | -2,000,000 | 121,000,000 | -148,000,000 | -21,000,000 | -21,000,000 | -33,000,000 | -34,000,000 | 16,000,000 | -15,000,000 | -33,000,000 | -41,000,000 | 16,000,000 | 1,000,000 | 27,000,000 | 2,000,000 | -18,000,000 | -15,000,000 | 15,000,000 | 16,000,000 | -15,000,000 | -19,000,000 | 23,000,000 | -6,000,000 | -70,000,000 | 1,000,000 | 12,000,000 | 18,000,000 | 2,000,000 | 5,200,000 | 156,500,000 | 32,552,000 | 44,432,000 | 5,476,000 | -122,000 | 61,151,000 | -7,457,000 | ||||||||||||
accounts payable, accrued and other liabilities | -150,000,000 | -284,000,000 | 144,000,000 | 163,000,000 | -99,000,000 | 24,000,000 | 144,000,000 | 138,000,000 | 51,000,000 | 97,000,000 | 166,000,000 | -97,000,000 | -8,000,000 | 47,000,000 | -96,000,000 | 49,000,000 | -75,000,000 | -170,000,000 | 46,000,000 | 130,000,000 | 115,000,000 | -185,000,000 | 70,000,000 | -271,000,000 | -85,000,000 | -116,000,000 | 26,000,000 | -55,000,000 | -4,000,000 | -228,000,000 | 84,000,000 | -66,000,000 | 89,000,000 | 88,000,000 | 143,000,000 | -40,000,000 | 196,000,000 | 60,000,000 | -25,900,000 | ||||||||||||||||
net cash from operating activities | 230,000,000 | 495,000,000 | 405,000,000 | 289,000,000 | 211,000,000 | 601,000,000 | 405,000,000 | 380,000,000 | 211,000,000 | 390,000,000 | 282,000,000 | 206,000,000 | 154,000,000 | 475,000,000 | -1,263,000,000 | 123,000,000 | -63,000,000 | 24,000,000 | 564,000,000 | 395,000,000 | 443,000,000 | 394,000,000 | 256,000,000 | 200,000,000 | 261,000,000 | 234,000,000 | 515,000,000 | 339,000,000 | 413,000,000 | 319,000,000 | 522,000,000 | 222,000,000 | 438,000,000 | 578,000,000 | 490,000,000 | 268,000,000 | 954,000,000 | 448,100,000 | 558,100,000 | 840,245,000 | -103,316,000 | 49,679,000 | 255,349,000 | 489,751,000 | -87,775,000 | -7,884,000 | 92,676,000 | ||||||||
capital expenditures | -109,000,000 | -92,000,000 | -91,000,000 | -99,000,000 | -115,000,000 | -106,000,000 | -71,000,000 | -78,000,000 | -82,000,000 | -98,000,000 | -42,000,000 | -28,000,000 | -47,000,000 | -66,000,000 | -54,000,000 | -52,000,000 | -46,000,000 | -78,000,000 | -63,000,000 | -62,000,000 | -66,000,000 | -80,000,000 | -81,000,000 | -69,000,000 | -72,000,000 | -78,000,000 | -83,000,000 | -62,000,000 | -47,000,000 | -62,000,000 | -32,000,000 | -30,000,000 | -33,000,000 | -53,000,000 | -43,000,000 | -37,000,000 | -38,000,000 | -66,000,000 | -62,300,000 | -90,387,000 | -12,171,000 | 1,281,000 | -14,042,000 | -50,569,000 | -43,468,000 | 0 | 0 | ||||||||
free cash flows | 121,000,000 | 403,000,000 | 314,000,000 | 190,000,000 | 96,000,000 | 495,000,000 | 334,000,000 | 302,000,000 | 129,000,000 | 292,000,000 | 240,000,000 | 178,000,000 | 107,000,000 | 409,000,000 | -1,317,000,000 | 71,000,000 | -109,000,000 | -54,000,000 | 501,000,000 | 333,000,000 | 377,000,000 | 314,000,000 | 175,000,000 | 131,000,000 | 189,000,000 | 156,000,000 | 432,000,000 | 277,000,000 | 366,000,000 | 257,000,000 | 490,000,000 | 192,000,000 | 405,000,000 | 525,000,000 | 447,000,000 | 231,000,000 | 916,000,000 | 382,100,000 | 495,800,000 | 749,858,000 | -115,487,000 | 50,960,000 | 241,307,000 | 439,182,000 | -131,243,000 | -7,884,000 | 92,676,000 | ||||||||
cash flows from investing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions and other investments | -187,000,000 | -5,000,000 | 0 | -12,000,000 | -91,000,000 | -1,856,000,000 | 0 | -31,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
purchases of property, plant and equipment | -109,000,000 | -92,000,000 | -91,000,000 | -99,000,000 | -115,000,000 | -106,000,000 | -71,000,000 | -78,000,000 | -82,000,000 | -98,000,000 | -42,000,000 | -28,000,000 | -47,000,000 | -66,000,000 | -54,000,000 | -52,000,000 | -46,000,000 | -78,000,000 | -63,000,000 | -62,000,000 | -66,000,000 | -80,000,000 | -81,000,000 | -69,000,000 | -72,000,000 | -78,000,000 | -83,000,000 | -62,000,000 | -47,000,000 | -62,000,000 | -32,000,000 | -30,000,000 | -33,000,000 | -53,000,000 | -43,000,000 | -37,000,000 | -38,000,000 | -66,000,000 | -62,300,000 | -90,387,000 | -12,171,000 | 1,281,000 | -14,042,000 | -50,569,000 | -43,468,000 | ||||||||||
acquisition of intangible assets and other assets | -38,000,000 | 0 | 0 | -1,000,000 | -9,000,000 | -1,000,000 | 0 | -1,000,000 | -1,000,000 | -61,000,000 | -14,000,000 | -19,000,000 | -5,000,000 | -10,000,000 | -131,000,000 | -3,000,000 | -7,300,000 | -64,784,000 | 27,657,000 | -31,802,000 | -707,000 | ||||||||||||||||||||||||||||||||||
purchases of marketable securities | -1,000,000 | -5,000,000 | -1,000,000 | -1,000,000 | -4,000,000 | -5,000,000 | -2,000,000 | -2,000,000 | -3,000,000 | -14,000,000 | -2,000,000 | 2,000,000 | -13,000,000 | -2,000,000 | -1,000,000 | -9,000,000 | -5,000,000 | -5,000,000 | -3,000,000 | -6,000,000 | -5,000,000 | -1,000,000 | -1,000,000 | 0 | -2,000,000 | -8,000,000 | -3,000,000 | -3,000,000 | -2,000,000 | -2,000,000 | -1,000,000 | -3,000,000 | -3,000,000 | ||||||||||||||||||||||
proceeds from sale of marketable securities | 1,000,000 | 2,000,000 | 1,000,000 | 1,000,000 | 4,000,000 | 3,000,000 | 4,000,000 | 1,000,000 | 6,000,000 | 13,000,000 | 4,000,000 | -2,000,000 | 11,000,000 | 2,000,000 | 7,000,000 | 7,000,000 | 6,000,000 | 4,000,000 | 3,000,000 | 6,000,000 | 2,000,000 | 1,000,000 | 1,000,000 | 4,000,000 | 2,000,000 | 7,000,000 | 2,000,000 | 0 | 1,000,000 | 2,000,000 | 1,000,000 | 2,000,000 | 2,000,000 | 0 | 1,000,000 | ||||||||||||||||||||
proceeds from sale of assets and businesses, net of costs to sell | 3,000,000 | 0 | 0 | 5,000,000 | 1,000,000 | 1,000,000 | 0 | 4,000,000 | 0 | 644,000,000 | 21,000,000 | 4,000,000 | 0 | 0 | 0 | 21,000,000 | 1,000,000 | 11,000,000 | 8,000,000 | 25,000,000 | 2,000,000 | 38,000,000 | 2,000,000 | -8,000,000 | 190,000,000 | 919,000,000 | 827,000,000 | 1,317,000,000 | 105,100,000 | 6,300,000 | |||||||||||||||||||||||||
interest settlements from cross-currency swaps | 5,000,000 | 0 | 6,000,000 | 0 | 6,000,000 | 0 | 7,000,000 | 0 | 6,000,000 | 0 | 7,000,000 | 0 | 6,000,000 | 12,000,000 | 0 | 11,000,000 | 0 | 12,000,000 | 0 | 11,000,000 | |||||||||||||||||||||||||||||||||||
net cash from investing activities | -139,000,000 | -282,000,000 | -83,000,000 | -100,000,000 | -130,000,000 | -200,000,000 | -102,000,000 | -79,000,000 | -73,000,000 | -148,000,000 | -1,889,000,000 | -30,000,000 | -78,000,000 | -136,000,000 | -53,000,000 | -58,000,000 | -56,000,000 | -80,000,000 | 588,000,000 | -43,000,000 | -56,000,000 | -84,000,000 | -70,000,000 | -67,000,000 | -40,000,000 | -85,000,000 | -73,000,000 | -58,000,000 | -203,000,000 | -62,000,000 | 5,000,000 | -91,000,000 | -48,000,000 | 90,000,000 | 869,000,000 | 780,000,000 | 1,148,000,000 | 49,900,000 | -112,000,000 | -911,277,000 | -3,937,376,000 | -296,837,000 | -234,896,000 | -2,668,325,000 | 178,745,000 | ||||||||||
cash flows from financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of long-term debt, net of discounts | 2,802,000,000 | 133,000,000 | -1,000,000 | 10,372,000,000 | 50,000,000 | 506,000,000 | 0 | 80,000,000 | 75,000,000 | 146,000,000 | 2,690,000,000 | 300,000,000 | 155,000,000 | 355,000,000 | 161,000,000 | 5,334,000,000 | 986,000,000 | 524,000,000 | -3,000,000 | 1,582,000,000 | -3,000,000 | 1,979,000,000 | -1,000,000 | 1,480,000,000 | -3,000,000 | ||||||||||||||||||||||||||||||
repayments of long-term debt | -2,857,000,000 | -352,000,000 | -704,000,000 | -9,967,000,000 | -168,000,000 | -411,000,000 | -164,000,000 | -495,000,000 | -390,000,000 | -203,000,000 | -817,000,000 | -411,000,000 | -279,000,000 | -622,000,000 | -141,000,000 | -6,598,000,000 | -485,000,000 | -240,000,000 | -1,100,000,000 | -1,900,000,000 | -200,000,000 | -2,480,000,000 | -100,000,000 | -1,603,000,000 | -1,459,000,000 | -450,000,000 | -453,000,000 | -1,882,000,000 | -1,621,000,000 | -1,901,000,000 | -364,000,000 | -6,105,000,000 | -1,731,000,000 | -4,954,000,000 | -1,410,000,000 | -220,000,000 | -7,619,000,000 | -847,500,000 | -425,600,000 | -1,545,194,000 | -4,606,318,000 | 255,329,000 | -430,036,000 | -1,898,055,000 | 96,118,000 | ||||||||||
payments of employee withholding taxes related to share-based awards | -34,000,000 | -5,000,000 | -3,000,000 | -16,000,000 | -5,000,000 | -4,000,000 | -14,000,000 | -8,000,000 | -3,000,000 | -12,000,000 | -1,000,000 | -4,000,000 | -25,000,000 | -3,000,000 | -4,000,000 | -41,000,000 | -1,000,000 | -5,000,000 | -24,000,000 | -1,000,000 | -5,000,000 | -34,000,000 | |||||||||||||||||||||||||||||||||
payments of acquisition-related contingent consideration | -8,000,000 | -8,000,000 | -6,000,000 | -5,000,000 | -7,000,000 | -7,000,000 | -8,000,000 | -5,000,000 | -7,000,000 | -18,000,000 | -6,000,000 | -4,000,000 | -7,000,000 | -7,000,000 | -6,000,000 | -5,000,000 | -8,000,000 | -6,000,000 | -36,000,000 | -35,000,000 | -6,000,000 | -5,000,000 | -7,000,000 | -6,000,000 | -17,000,000 | -7,000,000 | -11,000,000 | -9,000,000 | |||||||||||||||||||||||||||
payments of financing costs | -1,000,000 | -7,000,000 | -2,000,000 | -31,000,000 | -5,000,000 | 2,000,000 | -3,000,000 | 0 | -4,000,000 | 0 | -35,000,000 | 0 | -37,000,000 | -33,000,000 | -1,000,000 | 0 | -10,000,000 | -34,000,000 | -4,000,000 | 0 | 0 | -21,000,000 | -18,000,000 | -2,000,000 | 0 | -40,000,000 | -3,000,000 | -39,000,000 | -20,000,000 | -71,000,000 | 0 | -1,000,000 | -38,000,000 | -64,900,000 | -300,000 | ||||||||||||||||||||
other | -2,000,000 | -1,000,000 | -1,000,000 | -2,000,000 | -10,000,000 | -7,000,000 | 10,000,000 | -4,000,000 | 0 | -15,000,000 | -6,000,000 | 10,000,000 | -8,000,000 | -9,000,000 | -6,000,000 | -18,000,000 | -11,000,000 | 2,000,000 | -2,000,000 | -7,000,000 | 9,000,000 | 11,000,000 | 7,000,000 | 9,000,000 | 2,000,000 | -17,000,000 | 1,000,000 | -3,000,000 | -2,000,000 | -22,000,000 | -1,000,000 | -1,000,000 | -11,400,000 | 1,900,000 | 5,244,000 | -1,169,000 | -4,574,000 | 965,000 | -10,124,000 | -5,520,000 | 568,000 | 568,000 | 1,354,000 | 696,000 | 696,000 | ||||||||||
net cash from financing activities | -100,000,000 | -235,000,000 | -719,000,000 | 358,000,000 | -146,000,000 | 85,000,000 | -189,000,000 | -424,000,000 | -340,000,000 | -79,000,000 | 1,816,000,000 | -120,000,000 | -142,000,000 | -276,000,000 | -36,000,000 | -630,000,000 | 468,000,000 | 275,000,000 | -1,157,000,000 | -388,000,000 | -243,000,000 | -503,000,000 | -117,000,000 | -153,000,000 | -1,521,000,000 | 2,255,000,000 | -474,000,000 | -188,000,000 | -150,000,000 | -502,000,000 | -386,000,000 | -177,000,000 | -288,000,000 | -1,842,000,000 | -1,430,000,000 | -249,000,000 | -1,442,000,000 | -951,500,000 | 259,200,000 | 1,709,274,000 | -37,603,000 | 2,872,000,000 | -515,919,000 | 3,065,300,000 | -300,430,000 | ||||||||||
effect of exchange rate changes on cash, cash equivalents and restricted cash | -4,000,000 | -6,000,000 | 39,000,000 | 21,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | -13,000,000 | -44,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, beginning of period | 1,325,000,000 | 0 | 0 | 1,201,000,000 | 2,119,000,000 | 0 | 0 | 1,816,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, end of period | 1,312,000,000 | -403,000,000 | 586,000,000 | 1,157,000,000 | 127,000,000 | -132,000,000 | 755,000,000 | 2,460,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 1,299,000,000 | -419,000,000 | 593,000,000 | 1,134,000,000 | 124,000,000 | -138,000,000 | 733,000,000 | 181,000,000 | 61,000,000 | 518,000,000 | -173,000,000 | -590,000,000 | 1,249,000,000 | 48,000,000 | -37,000,000 | 679,000,000 | 81,000,000 | -16,000,000 | 912,000,000 | -53,000,000 | 96,000,000 | 782,000,000 | -135,051,000 | -77,481,000 | 431,537,000 | 870,175,000 | |||||||||||||||||||||||||||||
restricted cash | 13,000,000 | 16,000,000 | -7,000,000 | 23,000,000 | 3,000,000 | 6,000,000 | 22,000,000 | 11,000,000 | -4,000,000 | 13,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
net income | -103,000,000 | 181,000,000 | -342,000,000 | -351,000,000 | -760,000,000 | -2,691,000,000 | 512,000,000 | 1,300,000,000 | -37,000,000 | 629,000,000 | -304,000,000 | -372,900,000 | 108,306,000 | -982,841,000 | -123,670,000 | 29,252,000 | 16,272,000 | 54,513,000 | 91,156,000 | -81,665,000 | 56,376,000 | 56,376,000 | 28,092,000 | -1,957,000 | 93,819,000 | 93,819,000 | |||||||||||||||||||||||||||||
amortization and write-off of debt discounts and debt issuance costs | 17,000,000 | 18,000,000 | 21,000,000 | 23,000,000 | 51,000,000 | 34,000,000 | 23,000,000 | 43,000,000 | 36,100,000 | 20,500,000 | 61,889,000 | -5,707,000 | |||||||||||||||||||||||||||||||||||||||||||
asset impairments | 7,000,000 | 23,000,000 | 0 | 5,000,000 | 1,000,000 | 4,000,000 | 37,000,000 | 13,000,000 | 2,000,000 | 1,000,000 | 14,000,000 | 26,000,000 | 33,000,000 | 13,000,000 | 3,000,000 | 134,000,000 | 89,000,000 | 301,000,000 | 44,000,000 | 85,000,000 | 406,000,000 | 85,000,000 | 138,000,000 | ||||||||||||||||||||||||||||||||
goodwill impairment | 0 | 2,213,000,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
allowances for losses on trade receivables and inventories | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
additions to accrued legal settlements | 35,000,000 | 2,000,000 | 4,000,000 | 120,000,000 | 23,000,000 | 1,000,000 | 2,000,000 | -1,000,000 | 11,000,000 | 76,000,000 | 1,600,000 | 70,894,000 | 148,477,000 | -3,324,000 | 4,448,000 | ||||||||||||||||||||||||||||||||||||||||
gain on extinguishment of debt | 19,000,000 | -3,000,000 | 0 | 0 | -12,000,000 | -11,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
third party fees paid in connection with the 2022 exchange | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of employee withholding taxes related to share-based awards | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rate changes on cash and cash equivalents | -8,000,000 | -4,000,000 | -9,000,000 | 7,000,000 | -13,000,000 | 21,000,000 | 12,000,000 | 4,000,000 | -21,000,000 | 13,000,000 | -21,000,000 | 3,000,000 | 1,000,000 | -5,000,000 | -6,000,000 | -25,000,000 | 10,000,000 | 2,000,000 | 15,000,000 | 16,000,000 | 8,000,000 | -4,500,000 | 7,800,000 | -10,950,000 | 9,598,000 | 3,167,000 | -6,889,000 | 2,790,000 | 7,137,000 | 143,000 | -313,000 | 31,000 | 31,000 | ||||||||||||||||||||||
net increase in cash, cash equivalents and restricted cash | -15,000,000 | -403,000,000 | 341,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, beginning of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash, end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of interim contract and inventory step-up resulting from acquisitions | 20,000,000 | 20,000,000 | 22,000,000 | 21,000,000 | 21,000,000 | 20,000,000 | 20,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from b+l initial public offering, net of costs | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash, cash equivalents, restricted cash and other settlement deposits | 451,000,000 | 182,000,000 | -60,000,000 | 94,000,000 | -1,382,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, restricted cash and other settlement deposits, beginning of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, restricted cash and other settlement deposits, end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash and other settlement deposits, end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rate changes on cash, cash equivalents and other | 13,000,000 | -9,000,000 | -5,000,000 | -17,000,000 | 1,000,000 | 6,000,000 | -30,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, restricted cash and other settlement deposits, beginning of period | 0 | 0 | 962,000,000 | 0 | 0 | 0 | 591,000,000 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
net loss on sale of assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash, cash equivalents, restricted cash and other settlement deposits | -132,000,000 | -207,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
third party fees paid in connection with the exchange offer | 0 | 0 | -3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
asset impairments, including loss on assets held for sale | 0 | 1,000,000 | 6,000,000 | 8,000,000 | 21,000,000 | 18,000,000 | 47,000,000 | 148,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
acquisition of businesses, net of cash acquired | 0 | 0 | 0 | -180,000,000 | 0 | 0 | 0 | 5,000,000 | 0 | -18,500,000 | -814,218,000 | -3,925,868,000 | -275,854,000 | -237,603,000 | -3,239,919,000 | 208,653,000 | |||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, restricted cash and other settlement deposits, end of period | 182,000,000 | 192,000,000 | 57,000,000 | 531,000,000 | 94,000,000 | -1,382,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange loss | 8,000,000 | -2,000,000 | -2,000,000 | 1,000,000 | -5,000,000 | 12,000,000 | -6,000,000 | 3,000,000 | -5,000,000 | 16,000,000 | -1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||
payments for intangible and other assets | -4,000,000 | -3,000,000 | -4,000,000 | -5,000,000 | -4,000,000 | -11,000,000 | -5,000,000 | -2,000,000 | -2,000,000 | -1,000,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
foreign exchange gain | 6,000,000 | -1,000,000 | 10,000,000 | -25,000,000 | -13,000,000 | -39,000,000 | -31,000,000 | 12,306,000 | -1,770,000 | ||||||||||||||||||||||||||||||||||||||||||||||
restricted cash and other settlement deposits | -1,209,000,000 | 9,000,000 | 1,211,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
net proceeds from b+l initial public offering, net of costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, held for sale | 8,000,000 | 54,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
reductions to accrued legal settlements | -1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
settlements from cross-currency swaps | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings of short-term debt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of short-term debt | 0 | 0 | -4,000,000 | -2,000,000 | 0 | 0 | -1,000,000 | 0 | -1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents and restricted cash and other settlement deposits | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents and restricted cash and other settlement deposits, beginning of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents and restricted cash and other settlement deposits, end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuances of short-term debt | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash, cash equivalents, restricted cash and cash and cash equivalents held for sale | -29,000,000 | 131,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents, restricted cash and cash and cash equivalents held for sale, end of period | -29,000,000 | 1,947,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash, current | 0 | 1,214,000,000 | 0 | 0 | 1,011,000,000 | 0 | 0 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of assets | 10,551,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
additions (reductions) to accrued legal settlements | 1,389,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments of deferred consideration | 0 | 0 | -16,100,000 | -500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents and restricted cash | -172,000,000 | 81,000,000 | -16,000,000 | -1,321,000,000 | 2,417,000,000 | -53,000,000 | 96,000,000 | 61,000,000 | -250,000,000 | 135,000,000 | -1,172,000,000 | ||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents and restricted cash, beginning of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents and restricted cash, end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of assets | 0 | 0 | -1,000,000 | 1,000,000 | -10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents and restricted cash, beginning of period | 0 | 0 | 3,244,000,000 | 0 | 0 | 723,000,000 | 0 | 0 | 797,000,000 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents and restricted cash, end of period | 81,000,000 | -16,000,000 | 1,923,000,000 | -53,000,000 | 96,000,000 | 784,000,000 | 135,000,000 | -1,172,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||
interest expense on cross-currency swaps | -6,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of assets and businesses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
insurance proceeds for legal settlement | 0 | 40,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of share-based awards tax withholding | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments of contingent consideration | -11,000,000 | -8,000,000 | -7,000,000 | -11,000,000 | -11,000,000 | -9,000,000 | -17,000,000 | -8,000,000 | -18,800,000 | -25,600,000 | -114,930,000 | 46,755,000 | -40,831,000 | -21,054,000 | -85,100,000 | 14,692,000 | |||||||||||||||||||||||||||||||||||||||
loss on sale of assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net proceeds from the issuances of long-term debt | -5,000,000 | 1,729,000,000 | 1,514,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
debt extinguishment costs | -1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition accounting adjustment on inventory sold | 7,500,000 | 28,900,000 | 223,050,000 | 122,882,000 | -16,723,000 | 43,241,000 | 72,813,000 | -4,285,000 | |||||||||||||||||||||||||||||||||||||||||||||||
(reductions) additions to accrued legal settlements | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
reduction of cash due to deconsolidation | 0 | -30,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of stock options | 1,000,000 | -100,000 | 800,000 | 7,477,000 | 644,000 | -783,000 | 2,677,000 | 17,817,000 | 3,298,000 | ||||||||||||||||||||||||||||||||||||||||||||||
payment of employee withholding tax upon vesting of share-based awards | -3,000,000 | -5,000,000 | 0 | -1,000,000 | 400,000 | -7,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposals of assets and businesses | -317,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuances of long-term debt, net of discount | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments of employee withholding tax upon vesting of share-based awards | 296,000 | -7,835,000 | -6,848,000 | 2,534,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash, noncurrent | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposals of assets and businesses | -328,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of contingent consideration adjustments, including accretion | -1,000,000 | -1,000,000 | -1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of long-term debt, net of discount | 5,993,000,000 | 1,481,000,000 | 3,193,000,000 | -1,000,000 | -2,000,000 | 6,234,000,000 | 0 | 1,220,000,000 | 1,276,235,000 | 6,825,121,000 | 5,883,463,000 | -518,472,000 | |||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, end of period | -71,000,000 | 909,000,000 | -244,000,000 | -250,000,000 | 4,000,000 | 1,210,000,000 | -458,000,000 | 1,310,400,000 | -1,943,043,000 | 2,125,654,000 | 413,736,000 | -137,536,000 | -3,512,000 | -94,359,000 | 57,850,000 | -77,481,000 | 431,537,000 | 431,537,000 | -195,859,000 | -57,552,000 | 870,175,000 | 870,175,000 | |||||||||||||||||||||||||||||||||
restricted cash, end of period | -851,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | 112,000,000 | 668,000,000 | -458,000,000 | 713,100,000 | 1,627,292,000 | -4,068,697,000 | 2,628,009,000 | -502,355,000 | 889,516,000 | -202,323,000 | 35,635,000 | 35,635,000 | |||||||||||||||||||||||||||||||||||||||||||
net settlement of assumed derivative contracts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of convertible notes assumed | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock | 2,308,806,000 | -2,272,620,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
repurchases of common shares | 14,381,000 | -35,005,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on deconsolidation | 0 | 18,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash included in other non-current assets, end of period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
additions (reduction) to accrued legal settlements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash included in current assets, end of period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term debt borrowings | 1,500,000 | 700,000 | 22,649,000 | -9,407,000 | 9,700,000 | 4,471,000 | 26,435,000 | -3,306,000 | |||||||||||||||||||||||||||||||||||||||||||||||
short-term debt repayments | -1,000,000 | -1,200,000 | -700,000 | -49,882,000 | -14,403,000 | -9,438,000 | -1,417,000 | -26,255,000 | 16,762,000 | ||||||||||||||||||||||||||||||||||||||||||||||
tax benefit from share-based compensation | 0 | 1,400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of noncontrolling interest | -9,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, beginning of period | 542,000,000 | 0 | 597,300,000 | 2,125,654,000 | -502,355,000 | 916,091,000 | 64,787,000 | -244,776,000 | -2,104,000 | 433,641,000 | 433,641,000 | -400,717,000 | 834,540,000 | 834,540,000 | |||||||||||||||||||||||||||||||||||||||||
(reduction) additions to accrued legal settlements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales and maturities of short-term investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
settlement of foreign currency forward exchange contracts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of equity method investment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of equity method investment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in restricted cash | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, beginning of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization, including impairments of finite-lived intangible assets | 935,100,000 | 746,800,000 | 1,069,850,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
in-process research and development impairments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of assets and businesses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
allowances for losses on accounts receivable and inventories | 24,100,000 | 28,400,000 | 52,163,000 | 4,544,000 | 2,582,000 | 8,994,000 | 14,946,000 | 5,113,000 | |||||||||||||||||||||||||||||||||||||||||||||||
deferred income tax (benefit) expense | -138,400,000 | -26,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange (gain) loss | -13,700,000 | -1,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in restricted cash and cash equivalents | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash investing and financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of businesses, contingent and deferred consideration obligations at fair value | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of businesses, debt assumed | -42,583,000 | -4,217,113,000 | 32,525,000 | -37,554,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
payment of accreted interest on contingent consideration | -2,200,000 | -7,777,000 | -1,113,000 | -1,596,000 | -638,000 | -1,770,000 | 346,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income (income) to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefits from stock options exercised | 7,979,000 | -20,334,000 | -7,241,000 | -4,604,000 | -10,174,000 | 515,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
decrease | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
in-process research and development impairments and other charges | 29,658,000 | 119,151,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of marketable securities | -1,859,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | -314,341,000 | 97,736,000 | 44,452,000 | -89,227,000 | -36,785,000 | -190,829,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of assets | 10,572,000 | 8,429,000 | 81,279,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales and maturities of marketable securities | -1,034,000 | 9,027,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of marketable securities and other investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
repurchases of convertible debt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash settlement of convertible debt | -544,192,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash settlement of call options | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments of debt issuance costs | -81,161,000 | -46,528,000 | 32,986,000 | -33,311,000 | -10,591,000 | -21,455,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
distributions to noncontrolling interest | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of businesses, contingent consideration at fair value | -128,471,000 | 91,027,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
settlement of convertible debt, equity issued | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable, accrued liabilities and other liabilities | -101,233,000 | 38,182,000 | 9,193,000 | -113,422,000 | 93,387,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of businesses, contingent consideration obligations at fair value | 50,773,000 | -59,064,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | -23,591,000 | 341,445,000 | 750,911,000 | 13,445,000 | 11,204,000 | 272,000 | 25,073,000 | 25,073,000 | -3,156,000 | 21,885,000 | 21,885,000 | ||||||||||||||||||||||||||||||||||||||||||||
(gain) loss on sale of marketable securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of debt discounts and debt issuance costs | 9,647,000 | 9,370,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization and write-down of discounts and debt issuance costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale of marketable securities and other charges | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes payable | 21,011,000 | 14,810,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of intangible assets and other assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividends paid | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of valeant, equity issued | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of valeant, debt assumed | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired in-process research and development | 140,732,000 | -22,288,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of intangible assets | -5,610,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in restricted cash | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of deferred revenue | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization and write-down of deferred financing costs | 260,000 | -3,926,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of discounts on long-term obligations | 2,118,000 | 201,000 | 201,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment charges | -9,289,000 | 48,358,000 | 3,616,000 | 3,616,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation | -208,000 | 2,315,000 | 1,429,000 | 1,429,000 | -1,077,000 | 4,226,000 | 4,226,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of accrued legal settlements, net of insurance recoveries | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued contract costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity loss | 1,195,000 | 1,195,000 | -37,000 | 424,000 | 424,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities | 15,697,000 | 14,289,000 | 14,289,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of accrued legal settlements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization and write-down of discounts on long-term obligations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
additions to accrued legal settlements, net of insurance recoveries | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
premium paid on early extinguishment of debt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
contract recoveries | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
other current assets | -112,934,000 | 86,046,000 | 223,954,000 | 212,792,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
marketable securities | 76,000 | -693,000 | 23,758,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term investments | -14,417,000 | -9,028,000 | 23,637,000 | 55,227,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment | -14,791,000 | -51,501,000 | 233,799,000 | 212,988,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
intangible assets | 143,280,000 | -13,984,000 | 616,526,000 | 683,372,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill | 0 | 0 | 100,294,000 | 100,294,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
deferred tax assets, net of valuation allowance | 0 | 200,000 | 18,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term assets | -4,807,000 | -3,965,000 | 38,506,000 | 59,124,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders’ equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities | -162,685,000 | -39,250,000 | 390,225,000 | 742,214,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
long-term liabilities | 43,310,000 | -3,412,000 | 108,887,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders’ equity | -19,269,000 | -107,469,000 | 1,290,624,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of investment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued legal settlements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term investments | 79,725,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of deferred financing costs | 130,000 | 130,000 | 531,000 | 531,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
net cash provided by operating activities | 92,676,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase (decrease) in cash and cash equivalents | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term obligations | 1,337,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term liabilities | 107,953,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash from continuing operating activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued legal settlements, net of insurance recoveries | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
gains on disposal of investments and intangible assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment charges and asset write-offs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss from discontinued operation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from continuing operating activities | -54,862,000 | 119,828,000 | 119,828,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from continuing investing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from continuing financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from discontinued operation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from discontinued operation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of intangible assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to cash from continuing operating activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
contract costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss (income) from discontinued operation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to cash provided by continuing operating activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued contract losses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
receipt of leasehold inducements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired research and development | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
deposits and prepaid expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred revenue | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash provided by continuing operating activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
additions to property, plant and equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on disposal of intangible assets, net of withholding tax | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of long-term investments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of intangible assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of business, net of cash acquired | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
dividends paid | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of other long-term obligations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
financing costs paid | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
repurchase of senior subordinated notes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds (payment) on termination of interest rate swaps | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments under credit facility | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash used in continuing financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from discontinued operation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash used in operating activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash used in investing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash used in discontinued operation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders' equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders' equity | 1,342,468,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
product sales | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
total revenue | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating income | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating income excluding specific items | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per share | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted eps excluding specific items | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividends declared per share | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
total assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
product | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
sales | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
obligations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating income excluding specific items* | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted eps excluding specific items* |